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Abstract 
The overall aims of this dissertation are to determine the incidence and magnitude of insulin 
resistance (IR) in a cohort of normoglycemic college-age subjects with a family history of type 2 
diabetes, and to ascertain if there is early macro- and microvascular dysfunction relative to IR.  
Study 1 (Chapter 2) revealed a 7-fold range in IR in healthy college subjects concomitant with 
measures of insulin, both fasted and during an oral glucose tolerance test, but not related with 
any measure of plasma glucose.  These results emphasize that early in the etiology of 
carbohydrate dysregulation, abnormalities first occur with regard to insulin sensitivity.  Using 
brachial artery blood flow (BABF, Doppler fluxometry) and near-infrared spectroscopy (NIRS) 
(Chapter 3) we extended the understanding of the use of these non-invasive tools to assess 
forearm resting metabolic rate and to compare the parameters of both the NIRS oxy-hemoglobin 
signal, as a index of perfusion in the microcirculation, and BABF, as an independent measure of 
microvascular reactivity during post occlusive reactive hyperemia (PORH).  Resting metabolic 
rate ranged ~ 2 fold (2.83-5.15 μMO2/min/100g) similar to direct measures.  Amplitude, but not 
kinetic parameters for NIRS variables correlated with comparable parameters for BABF, 
providing evidence for the possible utility of NIRS in examining microvascular reactivity.  In 
study 3 (Chapter 4), utilizing our extended understanding of hemodynamics garnered from the 
results of study 2, we assessed the influence of IR on macro- and microvascular reactivity.  We 
observed that i) the magnitude of IR was significantly correlated with attenuation of 
endothelium-dependent vasodilation of the brachial artery (P< .01) indicating the possibility of a 
reduced nitric oxide bioavailability and an enhanced atherogenic milieu.  Additionally we found 
ii) BABF at rest and during reactive hyperemia to be strongly correlated with conductance 
(reduced downstream resistance—an indicator of microvascular control abnormalities) 
independent of forearm metabolic rate, and   iii) parameters of BABF (microvascular response) 
were also strongly correlated with brachial artery vasoreactivity (macrovascular response).  In 
conclusion, this body of work furthers our insight into the need for earlier identification of 
“disease” earlier in the progression to type 2 diabetes, and provides direction for future 
investigations into prevention / intervention to improve microvessel functionality and to slow the 
atherosclerotic process in larger vessels.  
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 Abstract 
The overall aims of this dissertation are to determine the incidence and magnitude of insulin 
resistance (IR) in a cohort of normoglycemic college-age subjects with a family history of type 2 
diabetes, and to ascertain if there is early macro- and microvascular dysfunction relative to IR.  
Study 1 (Chapter 2) revealed a 7-fold range in IR in healthy college subjects concomitant with 
measures of insulin, both fasted and during an oral glucose tolerance test, but not related with 
any measure of plasma glucose.  These results emphasize that early in the etiology of 
carbohydrate dysregulation, abnormalities first occur with regard to insulin sensitivity.  Using 
brachial artery blood flow (BABF, Doppler fluxometry) and near-infrared spectroscopy (NIRS) 
(Chapter 3) we extended the understanding of the use of these non-invasive tools to assess 
forearm resting metabolic rate and to compare the parameters of both the NIRS oxy-hemoglobin 
signal, as a index of perfusion in the microcirculation, and BABF, as an independent measure of 
microvascular reactivity during post occlusive reactive hyperemia (PORH).  Resting metabolic 
rate ranged ~ 2 fold (2.83-5.15 μMO2/min/100g) similar to direct measures.  Amplitude, but not 
kinetic parameters for NIRS variables correlated with comparable parameters for BABF, 
providing evidence for the possible utility of NIRS in examining microvascular reactivity.  In 
study 3 (Chapter 4), utilizing our extended understanding of hemodynamics garnered from the 
results of study 2, we assessed the influence of IR on macro- and microvascular reactivity.  We 
observed that i) the magnitude of IR was significantly correlated with attenuation of 
endothelium-dependent vasodilation of the brachial artery (P< .01) indicating the possibility of a 
reduced nitric oxide bioavailability and an enhanced atherogenic milieu.  Additionally we found 
ii) BABF at rest and during reactive hyperemia to be strongly correlated with conductance 
(reduced downstream resistance—an indicator of microvascular control abnormalities) 
independent of forearm metabolic rate, and   iii) parameters of BABF (microvascular response) 
were also strongly correlated with brachial artery vasoreactivity (macrovascular response).  In 
conclusion, this body of work furthers our insight into the need for earlier identification of 
“disease” earlier in the progression to type 2 diabetes, and provides direction for future 
investigations into prevention / intervention to improve microvessel functionality and to slow the 
atherosclerotic process in larger vessels. 
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CHAPTER 1 - Introduction 
There is recent substantive evidence to support the hypothesis that in the etiology of type 
2 diabetes, insulin resistance (IR) may increase for over a decade (23) before dysglycemia, at 
levels which identify impaired glucose tolerance (2, 17), is measured (21).  During the interim, 
normal glucose tolerance can be achieved when a change in insulin sensitivity is mirrored by a 
reciprocal change in insulin secretion (as reviewed by Bergman et al.(5)).  The current clinical 
protocol for identifying frank “disease” occurs commensurate to IR, which is not matched by 
compensatory hyperinsulinemia (19, 21) and postdates the progression through 
IR/hyperinsulinemia.   Yet, IR/hyperinsulinemia, in and of itself, is not only predictive of type 2 
diabetes (39) but is inexplicably linked to the presence of dyslipidemias (as reviewed by Scott, 
2006 (40)), hypertension and hypercoagulability, and attenuated endothelial function (10, 34).  
Thus, IR/hyperinsulinemic appears to be mechanistically (32) and epidemiologically (31) related 
to the risk of developing atherosclerosis and cardiovascular disease. 
Therefore, the early identification of IR in the healthy young adult (8) with a family 
history (genetic predisposition) of type 2 diabetes (38) is relevant to both medical practice and to 
preventative measures to improve the quality of life.  However, research in this area is minimal 
for people between ages late 20s-40s (as reviewed in (43)), and is virtually nonexistent in the 
youngest adults, in their late teens and early twenties.   
In this context, Study 1 (Chapter 2) was developed to ascertain the incidence and range of 
IR and hyperinsulinemia in a cohort of healthy, normoglycemic, college-age subjects with a 
family history of type 2 diabetes.  A simple and practical method of assessment was used, both in 
fasted and postprandial glucose stimulated states.  We hypothesized that there is a high 
prevalence of IR, indiscernible using dysglycemia criteria alone, in these young adults, but that 
fasting insulin or measures of insulin during an oral glucose tolerance test are highly sensitive 
means of quantifying IR. 
Impaired microvascular vasoreactivity can also predate disease states, such as type 2 
diabetes (9).  It has been hypothesized that microvascular dysfunction in skeletal muscle may be 
mechanistically linked to insulin resistance (42).  Due to ethical considerations, assessment of 
the microcirculation in humans to date is limited to superficial vascular beds and most often 
includes laser Doppler fluxmetry (skin pulp blood flow), transcutaneous oxygen tension (TcpO2), 
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iontophoresis (for the subdermal delivery of vasoactive drugs), and/or capillaroscopy (light 
microscopy) (1).  However, data acquired on vessels and tissues assessed by these methods (skin, 
finger nail fold or conjunctiva) may not necessarily be relevant to other areas, such as skeletal 
muscle in which control of the microcirculation may be different than for cutaneous beds (49).     
These limitations to the assessment of the microcirculation in skeletal muscle, the largest 
repository of glucose and potentially the most prognostic organ relative to the progression to type 
2 diabetes, was the impetus for Study 2 (Chapter 3).  In this study we assessed the validity and 
effectiveness of near infrared spectroscopy (NIRS) to estimate, non-invasively, skeletal muscle 
metabolic rate and skeletal muscle microcirculatory reactivity in humans. 
Although the utility of NIRS as a tool in physiological and clinical investigations (11) is 
not new (25) and although this methodology has gained acceptance for determining muscle 
metabolic rate (as reviewed in (20)), results via this technique do not correlate with the 
established method for measurements of muscle metabolic rate by the direct Fick method using 
blood flow and arterio-venous oxygen content differences (7, 47). There is also wide variability 
in reported values for NIRS derived forearm skeletal muscle metabolic rate (14-16, 24, 47)  
This variability with NIRS measures appear to be due, in part, to the fact that adipose 
tissue thickness (ATT) is a substantial confounding influence on in vivo NIRS measurements 
and must be factored into NIRS muscle studies (6). ATT has been demonstrated to quantitatively 
affect NIRS measures of oxygen consumption (VO2) in forearm skeletal muscle (46).  Correction 
methods for the influence of the fat layer on NIRS derived metabolic rate have been proposed (6, 
33, 41, 45, 50, 51). However, it is unclear whether any of these methods are definitive 
corrections or if they are applicable and necessary to Frequency Domain Multi Distance NIRS 
used in this study.  In Study 2 (Chapter 3) we determined quantitative measurements of forearm 
skeletal muscle metabolic rate, with appropriate correction for ATT, which correspond to values 
reported utilizing the direct Fick method.  This study also formed the methodological basis for 
Study 3 (Chapter 4). 
Post occlusive reactive hyperemia (PORH) has been used to evaluate the functional 
aspects of skeletal muscle microcirculation in conjunction with NIRS, but only relative to 
peripheral vascular disease (12, 26-28).  We propose that changes in the oxy-
hemoglobin/myoglobin ([HbO2]) signal in the initial phase of PORH reflect changes in perfusion 
in the microcirculation during this time period.  To test this, we compared measures of [HbO2] to 
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corresponding measures of brachial artery blood flow (as an independent measure of 
microvascular reactivity) during PORH, since upstream conduit artery flow (i.e. hyperemic 
response) should represent the integral of all the changes in perfusion in the downstream 
microvasculature (i.e. hyperemic stimulus) (13, 30, 48).   
Collectively, the findings reported in Chapter 3, have extended our understanding of a 
non-invasive technique for examining skeletal muscle metabolic and microvascular responses in 
humans.  NIRS has potential for examining dysfunction and to assess therapeutic interventions 
for efficacy in improving tissue oxygenation and hemodynamics. 
Since macro- and microvascular disease are the leading causes of morbidity and mortality 
in patients with type 2 diabetes (18), the capstone for the series of studies in this dissertation was 
the desire to ascertain whether IR, in young normoglycemic adults would have an impact on 
vasoreactivity.  
In the natural history to type 2 diabetes, metabolic and physiologic changes begin early 
and proceed in tandem (32). This process is exacerbated by, but not dependent on, 
hyperglycemia.  This association is corroborated by the conclusion that insulin resistance in 
young adults predicts coronary heart disease risk factors (3).  In this context, the question arose: 
How early can functional macro- and microangiopathy be detected relative to IR? 
The few previous studies that have looked at endothelial-dependent macrovascular 
dysfunction in normoglycemic subjects included those that ranged in age between the late 20s 
and old age (4, 9, 22, 29, 44).  The literature taken together is also unequivocal that impaired 
microvascular reactivity is clearly present in diabetes and prediabetes but there is sparse 
information that predates dysglycemia in the continuum toward frank disease.  Further, when 
reviewing the vast majority of literature involving flow mediated dilation there are crucial 
methodological considerations that must, but often have not, been considered.  For instance, the 
response is almost never standardized by the magnitude of the stimulus (shear or shear rate) that 
mediates the response even though there is compelling justification to do so (30, 35-37).  It is our 
contention that this shortcoming invalidates the results and conclusions of many of these 
investigations. 
In Chapter 4 we combined measurements of FMD, corrected for the stimulus, with the 
techniques developed in Chapter 3, to examine and compare conduit artery and microvascular 
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reactivity relative to the magnitude of IR in normoglycemic college-age students with a family 
history of type 2 diabetes 
The studies described herein were designed to further our understanding of insulin 
resistance and abnormalities in vascular reactivity before the onset of “pre-diabetes” in young 
normoglycemic college-age adults.  Each chapter is self-contained (Abstract, Introduction, 
Methods, Results, Discussion and Conclusions and References).   
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CHAPTER 2 - Insulin Resistance/Hyperinsulinemia in 
Normoglycemic College-age Subjects at Risk for Type 2 Diabetes 
 12
Abstract 
Little is known about insulin resistance (IR) in young adults before the onset of pre-diabetes.  
The goal of this study was to determine insulin sensitivity, measuring plasma insulin, in the 
fasting state and during an oral glucose tolerance test (OGTT), in normoglycemic college-aged 
subjects with a family history of type 2 diabetes.  Insulin sensitivity for 26 normal glucose 
tolerant (NGT), normotensive subjects, age 18-26 yrs., was calculated by homeostasis model 
assessment (ISIHOMA) and from the Matsuda and DeFronzo index [ISICOMP = 10,000/square root 
of (fasting glucose x fasting insulin) x (mean glucose x mean insulin during an OGTT)].  Body 
composition was assessed by dual-energy X-ray absorptiometry.  Subjects were normoglycemic 
in fasting (84.6 + 6.6 mg/dl) and at 2 hours OGTT (92.8 + 19.3 mg/dl).  Subjects exhibited a 7-
fold range in ISICOMP (10.3 + 4.6, range 3.6-21.8).  23% were determined IR by ISIHOMA ( < 0.58) 
and up to 54% by ISICOMP ( < 9.7).  ISICOMP was negatively correlated with fasting insulin (r=-
0.78) as well as average insulin, insulin area under the curve, and 2-hour insulin during an OGTT 
(r=-0.86, -0.79, -0.70 respectively, P < 0.0001) but not with fasting glucose (r=-0.28) or 2-h 
glucose (r=-0.34).  Inverse correlations were present with systolic blood pressure (r=-0.46, P < 
0.01) and triglyceride/HDL (r=-0.38, P < 0.05) as well as waist circumference, BMI, abdominal 
fat %, and total body fat % but only when obese subjects were included.  We conclude that IR is 
prevalent in NGT college-age subjects with family history of type 2 diabetes.   Fasting and 
OGTT measures of insulin are predictive of IR for this age group, while parallel measures of 
glucose are not discriminative. 
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Introduction 
“Pre-diabetes” (1) and Metabolic Syndrome X (2) include insulin resistance (IR), as 
identified by impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) as 
diagnostic criteria (3,4).  Normal glucose tolerance (NGT) can be achieved when a change in 
insulin sensitivity is mirrored by a reciprocal change in insulin secretion (as reviewed by 
Bergman et al.(5)).  “Disease” occurs when an increased IR is not matched by compensatory 
hyperinsulinemia (6,7).  
For individuals born in 2000, the estimated lifetime risk for type 2 diabetes, viewed by 
some as end-stage IR (8),  is ~33% for males and ~39% for females (9).  The hypothesis that IR 
may increase for over a decade before dysglycemia is detected, at levels that identify IGT (10), 
has gained recent support (7).  
IR/hyperinsulinemia, in and of itself, is not only predictive of type 2 diabetes (11) but 
there is a plethora of information linking IR to the presence of dyslipidemias (as reviewed by 
Scott, 2006(12)), hypertension and a hypercoagulable state, and attenuated endothelial function 
(13,14).  Thus, IR is mechanistically (8) and epidemiologically (15) related to the risk of 
developing atherosclerosis and cardiovascular disease. 
Given that the current clinical protocol for identifying “disease” postdates the progression 
through IR/hyperinsulinemia there is need for research on the seemingly healthy young adult 
(16) with a family history (FH) of type 2 diabetes (17).  Research in this area is nominal for 
people between ages late 20s-40s (as reviewed in (18)), and is virtually nonexistent in the 
youngest adults. This is justified as there is growing evidence that the progression to type 2 
diabetes could be reduced with lifestyle intervention (9,19,20) including diet and exercise (21) 
and by pharmacological intervention (22).  Thus, the focus for diabetes prevention should be on 
reducing IR (23) before insulin secretion begins to fail and blood glucose rises (24) in order to 
avoid macrovascular and microvascular complications.   
The focus of the present paper was to ascertain the prevalence and range of IR and 
hyperinsulinemia in a cohort of healthy, normoglycemic, college-age subjects with a family 
history of type 2 diabetes using a simple and practical method of assessment, both in fasted and 
postprandial glucose stimulated states.  Our hypotheses were (1) there is a high prevalence of IR 
and hyperinsulinemia present in college-age individuals with a family history of type 2 diabetes, 
(2) current clinical criteria for IR for pre-diabetes or the metabolic syndrome, using dysglycemia 
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alone, fail to identify IR even at levels associated with frank disease, and (3) fasting insulin or 
measures of insulin during an oral glucose tolerance test represent a highly sensitive means of 
quantifying IR in these young adults. 
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Materials and Methods 
Participants 
Twenty-six healthy, sedentary, college-age subjects (13 men, 13 women), age 18-26 yrs 
(21.6 + 2), participated in this study.  Twenty individuals were self-reported first-or second-
degree relatives of patients with type 2 diabetes (had FH) and 6 were of similar BMI and gender 
distribution with no known family history of type 2 diabetes (no FH). Three of the FH subjects 
were siblings (M, 1F).  All were recruited from the general population of students at Kansas 
State University.  Informed consent was obtained after written and verbal explanation about the 
possible risks and discomforts of the experimental protocol were given.  The study was approved 
by the Institutional Review Board for Research Involving Human Subjects at Kansas State 
University. 
Exclusion Criteria 
To minimize confounding factors for insulin sensitivity, potential subjects were excluded 
if they had a history of smoking, had performed regular exercise in the last 6 months of >3x20 
min. sessions/week of at least moderate intensity aerobic exercise, or had self-reported medical 
conditions of Acanthosis Nigricans, polycystic ovarian syndrome, or irregular menses with 
hirsutis.  Exclusion criteria also included current weight loss or dietary modifications, 
antioxidant therapies, or a diet that included a combination of >4 servings fruit and 
vegetables/day.  Subjects were also excluded if they were taking hormone therapy or hormonal 
contraception (except low dose combination ethinyl estradiol/progestin pills), antihypertensives, 
lipid lowering agents, drugs to control blood sugar (metformin, sulfurylureas), bronchial dilators, 
or psychoactive medications.  On the day of screening subjects were excluded if 12 hr. fasting 
glucose levels were >100 mg/dl, as measured by a hand held glucometer (FreeStyle Flash, 
TheraSense, Alameda, CA) or if blood pressure was >140/95 mmHg.  Data were rejected if 
measurements on subsequent days included results above the initial screening cut-off for 
exclusion or if biochemical analysis indicated triglycerides levels >300 mg/dl, cholesterol levels 
>210 mg/dl or 2 hr. post OGTT >140 mg/dl.  Four subjects, from an initial 30 screened, were 
excluded based on the above criteria.  Three overweight (OW) subjects (BMI, 25-29.9 kg/m2), 
three obesity (O) stage one subjects (BMI, 30-34.9 kg/m2), and one obesity stage two subject 
(BMI>35 kg/m2), were included and distributed proportionately within FH and no FH subjects to 
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better represent the current prevalence of overweight and obese in this age group. Nineteen lean 
(L) subjects (BMI<25) were included. 
Oral Glucose Tolerance Test (OGTT) and analytical procedures 
Subjects reported between 0700-0800 after a 10-12 hour fast and 24 hour abstinence from 
any exercise, alcohol and caffeine for a 2-hour oral glucose tolerance test (OGTT).  An 
indwelling antecubital venous catheter was inserted and kept patent with a continuous isotonic 
saline drip, and subjects rested at least 15 min. before the initiation of the test.  Baseline blood 
samples were collected for fasting serum glucose (FG) and fasting serum insulin (FI) at -15, -10, 
and -5 min. and the mean was used as the baseline blood sample. At t=0, ingestion of 1.75 g of 
glucose (SUN-DEX 10 g. glucose/fl. oz.) per kg body weight commenced and was completed in 
<5 minutes.  Samples were then drawn at t=30, 45, 60, 75, 90 and 120 min.  All samples were 
collected in serum separating tubes and the serum separated using refrigerated centrifugation at 
3,000 rpm for 10 min.  Samples were immediately analyzed for serum glucose (mg/dl) (YSI 
2300 glucose oxidase analyzer) and serum insulin (μU/ml) or stored in liquid nitrogen and 
processed later.  Serum insulin was measured by monoclonal, two-site, immuno-radiometric 
assay (Mercodia Insulin ELISA, ALPCO Diagnostics, Windham, NH) with detection limit <1 
μU/ml and intra assay CVs <5%. 
Anthropometry, blood analysis and criteria for the Metabolic Syndrome 
Height (cm), weight (kg), waist and hip circumference (cm), BMI, blood pressure and 
resting heart rate were measured.  Body composition was assessed by dual-energy X-ray 
absorptiometry (Prodogy, General Electric v. 5.6) and a region of interest was specified between 
the 7th rib and the iliac crest for measurement of visceral adiposity (abdominal fat %).  From the 
baseline blood samples, total cholesterol, HDL-cholesterol, C-reactive protein (CRP) and 
triglyceride levels were determined. LDL was calculated from Friedewald's formula (25). 
Criteria for the metabolic syndrome were defined from the National Cholesterol 
Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III, ATP III)(4).  
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Calculations 
Positive incremental areas under the curve (AUC-baseline) (26) during the OGTT were 
calculated with the trapezoidal method for glucose (GluAUCOGTT) and insulin (IAUCOGTT).  
AUC values were divided by the 120 min. and added back to fasting values to determine average 
glucose (GluAvOGTT ) and average insulin (IAvOGTT).  
Hepatic insulin sensitivity, ISIHOMA, was calculated as an inverse of the homeostatic 
model assessment, (27), as described by Radziuk (28): 
                     ISIHOMA =  FG)(FI
.
×
×18522
                       (1) 
Whole body insulin sensitivity, representing a composite of hepatic and peripheral tissues 
was calculated as ISICOMP (29): 
ISICOMP = 
000,10
)()( OGTTIOGTTGluFIFG AVAV ×××     (2) 
Statistical Analysis 
A Tukey-Kramer Multiple-Comparison Test was used to compare means between all 
subgroups of the data set (OW/O vs. L; FH vs. no FH) for each variable of interest (NCSS 2000, 
NCSS Statistical Software, Kaysville, UT, USA).  Significance was declared when P<0.05.  All 
numerical values are presented as mean + SD unless otherwise indicated. 
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Results 
Participant Characteristics 
Subject characteristics are shown in Table 2.1.  Seven individuals were OW/O and 19 
were L.  Twenty subjects had FH and 6 had no FH.  The male-female ratio for all subjects was 
evenly divided (13 females/13males) as were the ratio for all subsets of subjects.  The mean age, 
height, and resting heart rate were not significantly different (P>0.05) between any of the 
subgroups.  Neither weight, systolic blood pressure (BP) nor diastolic BP was significantly 
different between FH and no FH.  Weight was significantly different between OW/O and L 
(P<0.05) as was systolic BP (P<0.03).   
Anthropometry, measures of adiposity, and blood profile characteristics 
Table 2.1 shows that neither waist-hip ratio nor fat-free mass was significantly different 
between OW/O and L, but waist circumference, BMI, as well as all measurements of adiposity 
(total fat mass (%) and abdominal fat (%)) were significantly different (P<0.001).  There were no 
significant differences for any of the above stated anthropometric and body composition 
variables between FH and no FH.  Table 2.1 shows lipid profiles and CRP for the subcategories 
of subjects.  No significant differences were seen for any serum lipid measurements when 
comparing OW/O and L.  CRP was marginally not significantly different between OW/O and L 
(P =0.059).  No significant differences in any serum measurements were seen between FH and 
no FH except for triglycerides (P<0.01).  No subject met the clinical criteria for the metabolic 
syndrome.   Five subjects exhibited one of the criteria for the metabolic syndrome (two no FH) 
and four additional subjects had two of the criteria (one OW/three O).  Low HDL was the most 
common metabolic syndrome trait in these nine subjects (40.7+8.7, range 26-53 mg/dl).  Seven 
subjects had high levels (>3mg/dl) of CRP and of these, five had an additional metabolic 
syndrome marker. 
Metabolic characteristics in a fasted state and during an OGTT 
Metabolic characteristics, both in the fasted state and during the 2 hour postprandial 
OGTT, are shown in Table 2.1 and graphically represented for 2 subjects in Fig. 2.1.  FI for all 
subjects (5.12+2.44 μU/ml, range 2.43-12.51 μU/ml) were within the normal values listed for the 
immunoassay used (average 9.2, range 2-25 μU/ml).  FI, IAUCOGTT and IAVOGTT were 
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significantly different (P<0.05) between OW/O and L but not between FH and no FH.  For all 
subjects FI was significantly correlated with IAUCOGTT (r=0.59, P<0.005) and IAVOGTT 
(r=0.67, P<0.0005). 
FG (84.6+6.6 mg/dl, range 69.2-94.6 mg/dl) and Glu2HOGTT (92.8+19.3mg/dl, range 
61.3-124 mg/dl) indicated normoglycemia. There were no significant differences in any fasting 
or OGTT glucose measurements between OW/O and L or between FH and no FH. For all 
subjects, FG was not significantly correlated with GluAUCOGTT (r=0.04) or GluAVOGTT 
(r=0.28).  
There were no significant differences between any of the subcategories of subjects for 
ISIHOMA (1.02+0.47, range 0.37-2.07).  During the OGTT, there was a large range of insulin 
responses.  Fig. 2.1 compares an insulin sensitive (IS) subject with a more insulin resistant (IR) 
one.  The IR subject secreted almost 10 times the amount of insulin over baseline as the IS 
subject during the OGTT yet, even with this level of hyperinsulinemia, the increase in serum 
glucose for the IR subject was 5.5 fold greater than that of the IS subject.  For all subjects there 
was over a 7-fold range of ISICOMP (10.3+4.6, range 2.95-21.8).  There was no difference in 
ISICOMP between FH and no FH.  Lean subjects were more insulin sensitive (P<0.05) than OW/O 
subjects (ISICOMP= 11.7+4.5 and 6.54+1.92 respectively, Fig. 2.2).  ISIHOMA was significantly 
correlated with ISICOMP for all subjects (r=0.68, P<0.0005) and for each subcategory of subjects.  
CRP was not significantly correlated with ISICOMP either in the group with high CRP (>3 mg/dl) 
or for the pool of all subjects. 
Measurements of glucose and insulin relative to insulin sensitivity 
FG showed no correlation with ISICOMP for all subjects (r=-0.28) (Fig. 2.3) or for lean 
subjects (r=-0.41), while FI was highly correlated with ISICOMP (P<0.0001) for all subjects (r=-
0.78) (Fig. 2.3) as well as lean subjects (4.49+1.93 μU/ml range 2.43 – 9.25 μU/ml) (r=-0.80). 
2-h glucose (Glu2-HOGTT) was not significantly correlated with ISICOMP either for all 
subjects (r=-0.34) or lean subjects only (r=-0.24). GluAVOGTT is currently not used to clinically 
assess insulin sensitivity; however, in this study, this measurement was negatively correlated 
with ISICOMP (r=-0.45, P<0.03) (Fig. 2.3).   IAVOGTT (Fig. 2.3) as well as IAUCOGTT and 2-h 
insulin (I2-HOGTT) (data not shown) were all highly sensitive correlates (r=-0.86,-0.79, -0.70, all 
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P<0.0001 respectively) with ISICOMP for all subjects as well the subset of lean subjects.  Both of 
these measurements of insulin during the OGTT were better predictors of ISICOMP than was FI. 
Adiposity and blood profile characteristics with insulin sensitivity 
Most measurements of adiposity such as waist circumference (r=-0.52, P<0.005), BMI 
(r=-0.49, P<0.01), and abdominal fat % (r=-0.43, P<0.02) were correlated or almost significantly 
correlated (total body fat %, r=-0.36, P<0.06) with ISICOMP, while waist/hip ratio was not.  
However, when L alone or L combined with OW subjects were analyzed; none of these markers 
of adiposity correlated with ISICOMP.  All subjects were normotensive yet systolic BP (120+9 
mmHg, range 96-130 mmHg) was still significantly correlated with ISICOMP for all subjects (r=-
0.46, P<0.01) as well as for lean subjects (r=-0.40, P<0.01).  Neither diastolic BP, nor blood 
lipids associated with the clinical criteria of the metabolic syndrome were correlated with 
ISICOMP, either for the subjects as a whole or any subsets, while triglyceride/HDL ratio was (r=-
0.38, P<0.05). 
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Discussion 
Our major findings are consistent with our hypotheses and demonstrate that (1) there is 
significant prevalence of IR and hyperinsulinemia in a cohort of lean, apparently healthy, 
college-age individuals with a family history of type 2 diabetes and that (2) current clinical 
criteria for either pre-diabetes or the metabolic syndrome, as measured by dysglycemia alone 
(fasting or postprandial), fail to identify IR even at levels associated with frank disease.  We also 
determined that (3) fasting insulin and measures of insulin during an OGTT are highly sensitive 
means of quantifying IR in these young adults. 
Our data revealed, in NGT college-age subjects, a 7-fold range in insulin sensitivity 
(ISICOMP=2.95-21.8), similar to the 6-7-fold range found in older NGT subjects (30). In 
conjunction with the wide range of IR in our subjects, IAUCOGTT ranged between 445-8960 
µU/ml-120 min. above baseline, a 20-fold difference among subjects. As can be seen in Fig. 2.1, 
there was a ~10-fold difference in insulin during the OGTT between the most IR and the most IS 
subject yet both were clinically normoglycemic in a fasted state (<100 mg/dl), during the OGTT 
(<200 mg/dl) and at 120 min. OGTT (<140 mg/dl) (31).  
A large proportion of our subjects exhibited ISICOMP values similar to levels associated 
with metabolic disorder and frank disease reported in other studies. 58% of our subjects, 
including all OW/O subjects, had ISICOMP <9.7, the cut-off that correlated with IFG reported by 
Piche et al. (32).  What is noteworthy is that IR was present in our subjects irrespective of the 
confounding influence of increased BMI since 37% of our lean subjects were also IR by these 
criteria.  Tripathy et al. (33) determined even lower values for ISICOMP (4.6+1.6) associated with 
IFG yet 19% of our subjects were still IR by the latter criteria (ISICOMP <6.2) and two of these 
were lean.  A review of threshold values for HOMA-IR (34) determined an equivalent ISIHOMA 
range of cut-off to be between 0.36-0.58 and, more recently defined as <0.31 (35) and <0.30 for 
the same measure (36).  19% of our subjects were below the cut-off for IR based on the above 
studies.  
The prevalence of IR has been previously reported in “young adults” between the ages of 
17 and 39 years but only as defined by IFG or IGT (37-39).  It is estimated that the prevalence of 
IFG is only 2.8% for adults aged 20-39 (38).  However, the relative paucity of “pre-diabetes” in 
this age group may partially reflect our present clinical focus on dysglycemia as the diagnostic 
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marker. To this point, our subjects were all normoglycemic, even though there was prevalent IR 
of the magnitude associated with disease in older adults.  
 Direct quantification of IR in the natural history of type 2 diabetes is currently not 
clinically recommended (31).  However, FI may prove to be a useful diagnostic tool (40), as our 
data, and those of others (41) demonstrate that IR can be detected from this simple measurement.  
We found that measures of insulin, both fasting and during the OGTT, were highly sensitive 
markers of IR, even in lean individuals, while parallel measures of glucose were not.  
 To our knowledge this is the first study to verify the presence of IR in college–age adults 
with an easily applicable indirect measure.  IR has previously been studied in normoglycemic 
“young” adults.  Some of these studies included overweight subjects (42-47) and others included 
only lean subjects (48-51) but all of these studies focused on subjects in their late 20s to mid 30s.  
It is known that ISICOMP is attenuated by age (52).  In one study markedly higher FI and 
increased IR have been reported in subjects age ~24 years (18).  However, these findings were 
obtained with a clinically impractical direct method of measuring IR (euglycemic 
hyperinsulinemic clamp). 
 There is growing evidence that acquired factors, such as increased adiposity, are 
concomitant and mechanistically linked with IR (as reviewed in (9,53)).  Strong correlations 
have been found between ISICOMP and BMI (52,54) as well as waist-to-hip ratio (55). It should be 
noted from Fig. 2.2, that even though OW/O subjects had lower insulin sensitivity than lean there 
were 7 lean subjects with values equally low as OW/O, suggesting that while increased BMI is 
associated with IR, lower BMI does not prevent the occurrence.  Nonetheless, in the present 
study, none of the measures of adiposity were good predictors of IR until clinical obesity.  
 High blood pressure and blood lipid levels are associated with IR in the metabolic 
syndrome.  Even though all subjects were normotensive in the present study, systolic BP was 
found to be a prognostic marker of IR, even for just the lean individuals.  Triglyceride/HDL 
ratio, the best lipid derived IR predictor (56), was also correlated with ISICOMP for all subjects. 
 There is a lack of standardization of the plasma insulin assay (56) and insulin values in 
the literature are variable. Insulin values, obtained by radioimmunoassay, are 20-40% higher 
than the newer, more widely used, two-site immuno-radiometric assay (57) utilized in the present 
study.  ISICOMP was originally derived from plasma insulin values obtained with 
radioimmunoassay and formulated to produce a number between 0 and 12.  This, undoubtedly, is 
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the reason that 10 of the 26 subjects from the present study had ISICOMP values above 12 and why 
interpretation of this study in the context of previous literature is limited.  
 There is a wide discrepancy in ISICOMP values reported in studies with NGT subjects 
(32,33) even when the insulin assay protocols were similar (52,54,55).  Differences in subject 
age, BMI and ethnicity likely contributed to the variability.  Thus, these factors, as well as 
gender, were taken into account in the present study design.   
 Correlations between insulin levels and calculations of insulin sensitivity were not 
independently derived in the present study. Both FI and FG are equally weighted in the 
computation for ISICOMP (Eq. 2).  However, FG was not significantly correlated with ISICOMP 
while FI was strongly correlated ( Fig. 2.3) even though latter values were numerically much 
smaller and thus had much less influence on the calculation.  This was true even within the 
subset of lean individuals who had even lower FI. 
 There is a plethora of data relating the development of IR, diabetes and the metabolic 
syndrome with visceral and subcutaneous fat, BMI, and waist circumference (as reviewed by 
(53)).  Since the purpose of the present study was not to confirm the previously determined affect 
of adiposity on ISICOMP, the distribution of BMI was purposefully determined (both for FH and 
no FH) to represent an approximation of the prevalence of a BMI for OW/O in the U.S. 
population for a college-age (18-26 yrs.) cohort (as reported in the National Center for Health 
Statistics, unpublished tabulations). 
In summary, we demonstrated that a) IR could be detected in college-aged individuals by 
an easily applied clinical method measuring serum insulin, b) substantial levels of IR and 
hyperinsulinemia are prevalent in college-age subjects preceding the deterioration of glucose 
tolerance and c) this metabolic profile is present despite the absence of adiposity and no family 
history of type 2 diabetes.  
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Tables 
Table 2.1 Subject Characteristics 
 
Subject Characteristics All subjects OW / O Lean FH noFH 
No. of subjects  n=26 n=7 n=19 n=20 n=6 
Gender (female / male) 13/13 4 / 3 9 / 10 10 / 10 3 / 3 
FH type 2 diabetes / no FH 20 / 6 5 / 2 15 / 4 N/A N/A 
Age (yr) 21.6 + 2.0 22.9 + 2.0 21.2 + 1.8 21.3 + 1.7 22.8 + 2.6 
Height (cm) 175 + 9 176 + 11 175 + 9 175 + 10 177 + 8 
Weight (kg) 75.5 + 18.2 94.8 + 21.1* 68.4 + 10.7 75.6 + 18.9 74.9 + 17.5  
Resting heart rate (bpm) 65.9 + 8.4 67.7 + 6.3 65.3 + 9.2 65.4 + 9.4 67.9 + 3.0 
Systolic BP (mmHg) 120 + 9 126 + 8* 117 + 8 119 + 10 121 + 7 
Diastolic BP (mmHg) 72.6 + 9.0 74.6 + 12.4 71.9 + 7.8 71.6 + 9.4 76.2 + 7.1 
Anthropometry      
Waist circumference (cm) 81.9 + 12.6 93.8 + 15.5† 77.2 + 7.7 81.3 + 13.1 83.6 + 12.0 
Waist-hip ratio 0.79 + 0.08 0.81 + 0.10 0.78 + 0.07 0.79 + 0.08 0.80 + 0.06 
BMI (kg/m2) 24.4 + 4.4 30.2 + 4.0† 22.2 + 2.0 24.6 + 4.6 23.7 + 4.1 
Total fat mass (%) 27.8 + 9.6 38.6 + 8.6† 23.9 + 6.5 28.0 + 9.9 27.3 + 9.6 
Abdominal fat (%) 35.1 + 11.0 48.1 + 7.4† 30.3 + 7.7 35.4 + 11.1 33.9 + 11.7 
Fat free mass (kg x 102) 516 + 117 562 +161 500 + 96 516 + 121 517 + 108 
Blood lipids and CRP      
Cholesterol (mg/dl) 155 +29 163 + 35 153 + 27 152 + 29 168 + 29 
Triglycerides (mg/dl) 84.9 + 42.5 106 + 57 77.2 + 34.6 74.0+ 26.2  121.5+ 65.9‡ 
HDL (mg/dl) 51.9 +13.2 47.0 + 14.6 53.7 + 12.6 50.9 + 13.8 55.2 + 11.4 
LDLcalc (mg/dl) 86.6 + 23.9 95.2 + 19.3 83.4 + 25.1 86.1 + 25.4 88.2 + 19.8 
TC/HDL 3.20 + 0.91 3.61 + 0.73 2.99 + 0.93 3.17 + 0.97 3.13 + 0.77 
LDL/HDL 1.81 + 0.80 2.16 + 0.67 1.68 + 0.82 1.85 + 0.86 1.66 + 0.55 
Triglycerides / HDL 1.74 + 0.96 2.28 + 0.91 1.54 + 0.92 1.57 + 0.70 2.33 + 1.49 
C-reactive protein 3.56 + 5.61 6.95 + 8.69 2.30 + 3.52 4.16+ 6.16  1.53 + 2.56 
Metabolic Characteristics      
FI (µU/ml)  5.12 + 2.44 6.83 + 3.02§ 4.49 + 1.93 5.12+ 2.67  5.12 + 1.69 
IAUCOGTT (μU/ml) 2968 + 2115 4400 + 2550§ 2441 + 2952 + 2053 3024 + 2520 
IAVOGTT (μU/ml) 29.9 + 19.2 43.5 + 23.0§ 24.8 +15.3 29.7 + 18.7 30.3 + 22.4 
I2HOGTT (μU/ml) 21.7 + 16.1 30.1 + 15.0 18.6 + 15.7 21.1 + 14.1 24.0 + 23.2 
FG (mg/dl) 84.6 + 6.6 86.5 + 9.4 83.9 + 5.4 83.8 + 6.5 87.3 + 6.6 
GluAUCOGTT (μU/ml) 3782 + 2304 4534 + 2828 3505 + 4052 + 2253 2883 + 2449 
GluAVOGTT (mg/dl) 116 + 21 124 + 24 113 + 19 117 + 20 111 + 23 
Glu2HOGTT (mg/dl) 92.8 + 19.3 103 + 17 89.2 + 19.1 93.5 + 18.6 90.6 + 23.2 
ISIHOMA 1.02 + 0.47 0.84 + 0.45 1.17 + 0.44 1.10 + 0.50 1.00 + 0.34 
ISICOMP 10.3 + 4.6 6.54 + 1.92§ 11.7 + 4.5 10.4 + 4.8 9.97 + 3.91 
 
Table 2.1 values are mean + SD; OW / O-Overweight/Obese; FH-family history of type 2 diabetes; no 
FH-no family history; FI-fasting insulin; IAUCOGTT, IAVOGTT, I2HOGTT- insulin area under the curve 
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above fasting, average insulin, and insulin at two hours respectively, during an oral glucose tolerance test; 
FG-fasting glucose; GluAUCOGTT, GluAVOGTT, Glu2HOGTT-glucose area under the curve above fasting, 
average glucose and glucose at two hours respectively, during an oral glucose tolerance test. ISIHOMA-
insulin sensitivity index from fasting measures.   ISICOMP –composite insulin sensitivity index.  
*Significantly different from lean (P < 0.05); † Significantly different from lean (P < 0.001); 
‡Significantly different from FH (P < 0.01); § Significantly different from lean (P = 0.03). 
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Figures 
Figure 2.1 Comparison of changes in serum glucose and serum insulin in one insulin 
sensitive and one insulin resistant normoglycemic subject during an oral glucose tolerance 
test. 
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insulin sensitive (IS-white, ISICOMP = 21.82),  insulin resistant (IR-gray, ISICOMP = 3.54) . FG-
fasting glucose; GLUAUCOGTT, GLUAVOGTT - glucose area under the curve above fasting and 
average level of glucose respectively, during an oral glucose tolerance test; FI-fasting insulin, 
IAUCOGTT, IAVOGTT - insulin area under the curve above fasting and average level of insulin 
respectively, during an oral glucose tolerance test. 
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Figure 2.2 Mean, SD and range for ISICOMP for each subgroup and for all 
subjects. 
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Figure 2.3 Fasting and average measurements of glucose and insulin during an oral glucose 
tolerance test relative to ISICOMP. 
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Fasting measurements (top) and average measurements during an oral glucose tolerance test 
(OGTT) (bottom) of glucose (mg/dl) (left panels) and insulin (μU/ml) (right panels) relative to 
composite insulin sensitivity index. (ISICOMP). 
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Figure 2.4 Measures of insulin sensitivity in a fasted state (ISIHOMA) and during an oral 
glucose tolerance test (ISICOMP). 
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CHAPTER 3 - Metabolic Rate and Parameters of Post Occlusive 
Reactive Hyperemia (PORH) in Forearm Skeletal Muscle 
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Abstract 
OBJECTIVE—Few previous studies have used near-infrared spectroscopy (NIRS) to determine 
forearm skeletal muscle metabolic rate (MR) or parameters of post occlusive reactive hyperemia 
(PORH).  Additionally, these previous results are potentially inaccurate based consequent to 
methodological problems. The goal of this study was to use Frequency Domain Multi Distance 
(FDMD) NIRS to (1) determine quantitative measurements of forearm skeletal muscle MR, 
corrected for the effect of adipose tissue thickness (ATT) and (2) determine NIRS parameters 
describing PORH as a noninvasive measure of microcirculatory function. 
 
RESEARCH DESIGN AND METHODS—Twenty six, young (age 18-26 yrs.) normotensive 
subjects, underwent 3 trials of upper limb PORH and were assessed with pulsed Doppler 
ultrasound for brachial artery (BA) velocity and diameter, and with FDMD NIRS for changes in 
forearm oxy-hemoglobin/myoglobin ([HbO2]), deoxy-hemoglobin/myoglobin ([Hb]) and total 
hemoglobin ([THb]) before and during the PORH protocol.  Forearm skeletal muscle MR was 
derived from the initial linear increase in [HHb] during occlusion, while parameters of the 
[HbO2] PORH response (i.e. time course and peak of the initial response and measure of 
recovery) were described using a sigmoidal function.  All NIRS measures were corrected for 
ATT.  Parameters describing PORH brachial artery blood flow (BABF) dynamics were also 
determined as an independent measure of microvascular reactivity.  
 
RESULTS—Subjects exhibited an ~ 2-fold range in ATT-corrected MR (3.70 + 0.54, range 
2.83-5.15 μMO2/min/100g). Ignoring the influence of ATT on NIRS signals led to several false 
positive and negative comparisons.  ATT-corrected [HbO2] at rest and the amplitude of the 
PORH response [referenced either from end cuff (both P<0.0001) or from rest (P<0.001)] were 
positively correlated with MR.  [HbO2] at end cuff was negatively correlated with MR (P<0.01).  
Further, the amplitude of the response for [HbO2] [scaled either to rest or end-cuff] correlated 
with the corresponding parameters for BABF (P<0.01 and P<0.04 respectively).  However, none 
of the time course parameters, nor [HbO2] 95 s into recovery, correlated with either MR or 
corresponding parameters for BABF. 
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CONCLUSIONS—These findings indicate that 1)  It is imperative to correct NIRS signals for 
ATT.  2)  The validity of the NIRS [HbO2] response as an index of capillary perfusion and thus, 
a measure of microvascular reactivity, under certain conditions, is supported by the correlation 
between [HbO2] parameters and metabolic rate as well as with corresponding parameters of the 
BABF response. 3)  However, the disparity between the kinetics of adjustment of [HbO2] and 
BABF during PORH suggest that the vascular compartment sampled by NIRS may not reflect 
the sum total of all the forearm vasculature during the response. 
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Introduction 
In disease states, microcirculatory perfusion can be disturbed (5, 32) and the capillary 
density within skeletal muscle reduced (15). Impaired microvascular vasoreactivity can predate 
disease states, such as type 2 diabetes (4), such that microvascular dysfunction in skeletal muscle 
may be mechanistically linked to insulin resistance (30). 
Assessment of the microcirculation in humans most often includes laser Doppler 
fluxmetry (skin pulp blood flow), transcutaneous oxygen tension (TcpO2), iontophoresis (for the 
subdermal delivery of vasoactive drugs), and/or capillaroscopy (light microscopy) (1).  However, 
data acquired on vessels and tissues assessed by these methods (skin, finger nail fold or 
conjunctiva) may not necessarily be relevant to other areas, such as skeletal muscle in which 
control of the microcirculation may be different than for cutaneous beds (39).    Thus, the need 
exists to develop non-invasive methods for examining skeletal muscle microvascular responses 
in humans both as a prognostic tool and to assess therapeutic interventions for efficacy in 
improving tissue oxygenation and hemodynamics. 
The pioneering work of Jobsis in 1977 (20), put forward near infrared spectroscopy 
(NIRS), as a simple, noninvasive technique, with many possible applications.  Evaluation of 
muscle metabolic rate (MR) (or oxygen uptake (VO2)) can be very useful in physiological and 
clinical investigations.  Cheatle et al (6) was the first to measure VO2 at rest in calf muscle by 
NIRS.  Since then, the utility of the NIRS methodology for determining muscle MR has gained 
greater acceptance (as reviewed in (14)).  NIRS determined oxygen uptake of forearm flexor 
muscles has been correlated with P-MRS (3, 16) but does not correlate with the established 
method for measurements of muscle MR by the Fick method, determined by blood flow and 
arterio-venous oxygen content differences (3, 36). There is also wide variability in reported 
values for NIRS derived forearm skeletal muscle MR (10, 11, 13, 19, 36) likely due to variable 
thickness of subcutaneous fat under the probe interfering with the NIRS signal. 
Adipose tissue thickness (ATT) is a substantial confounding influence of in vivo NIRS 
measurements and must be factored into NIRS muscle studies (2). ATT has been demonstrated 
to quantitatively affect NIRS measures of VO2 in forearm skeletal muscle (34).   Correction 
methods for the influence of the adipose layer on NIRS derived MR have been proposed for 
continuous wave NIRS (2, 28, 29, 33, 40).   Recently a method was proposed to correct for fat 
pad thickness by removing the spectral influence of the fat layer from the muscle spectrum 
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before measuring the physiological parameters (41). However, it is unclear whether any of these 
methods are applicable to Frequency Domain Multi Distance (FDMD) NIRS data.   
Post occlusive reactive hyperemia (PORH) has been used to evaluate the functional 
aspects of skeletal muscle microcirculation in conjunction with NIRS, but only relative to 
peripheral vascular disease (PVD)(7, 22-24).  These studies evaluated PORH responses using 
some measure of the rate of O2 resaturation (as %Sat).  However, it is unlikely that %Sat is a 
robust measure of the hyperemic response.  While none of the NIRS signals are a true measure of 
blood flow, changes in %Sat reflects changes in both oxygen uptake and arterial inflow.  These 
also are confounded by changes occurring in total hemoglobin most likely reflecting changes in 
tissue capillary hematocrit (21).  Therefore, % Sat is likely not to be a good surrogate index for 
perfusion.  We propose that changes in the oxy-hemoglobin/myoglobin ([HbO2]) signal in the 
initial phase of PORH more closely reflect changes in perfusion in the microcirculation during 
this time period.  To test this, we compared these measures of [HbO2] to corresponding measures 
of brachial artery (BA) blood flow (BF) during PORH,  since upstream conduit artery flow (i.e. 
hyperemic response) should also provide information about the changes in perfusion in the 
downstream microvasculature (i.e., hyperemic stimulus) (9, 26, 37). 
The purposes of the present study were to utilize FDMD NIRS to (1) determine 
quantitative measurements of forearm skeletal muscle MR, with appropriate correction for ATT, 
in young, healthy college-age subjects, (2) characterize PORH response of the microcirculation 
using [HbO2], and (3) compare [HbO2] responses with corresponding responses in the conduit 
(brachial) artery as an independent measure of PORH microvascular reactivity.  We 
hypothesized that (1) characteristics of [HbO2] during occlusion will inversely correlate with 
MR, (2) kinetic characteristics of the PORH [HbO2] response, including time course and peak, 
will positively correlate with MR, and (3) characteristics of the [HbO2] (microvascular) response 
will correlate with corresponding characteristics of the BABF (macrovascular) response. 
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Methods 
Subjects 
Twenty-six healthy, sedentary, college-age subjects (13 men, 13 women), age 18-26 yrs., 
participated in this study.  Exclusion criteria were employed to mitigate influences on endothelial 
function.   These included a history of smoking, regular exercise in the last 6 months of > 3x20 
min. sessions/week of at least moderate intensity aerobic exercise, or those taking 
antihypertensive medications, lipid lowering agents, drugs to control blood sugar (metformin, 
sulfurylureas), bronchial dilators, or psychoactive medications.  Women were excluded if they 
were taking hormone therapy or hormonal contraception (except low dose combination ethinyl 
estradiol / progestin pills) and were studied during the early follicular phase of their menstrual 
cycle as verified by progesterone (P4) levels < 1.5 ng/ml.  All subjects were recruited from the 
general population of students at Kansas State University.  Informed consent was obtained after 
both written and verbal explanation about the possible risks and discomforts of the experimental 
protocol were given.  The study was approved by the Institutional Review Board for Research 
Involving Human Subjects at Kansas State University.   
Anthropometry 
Measurements of height (cm), weight (kg), waist and hip circumference (cm), BMI, 
blood pressure and resting heart rate were taken.  Body composition was assessed by dual-energy 
X-ray absorptiometry (Prodogy, General Electric v. 5.6) and a region of interest was specified  
distal to the olecranon process for forearm skeletal muscle mass.  Progesterone (P4) 
(Progesterone RIA DSL-3900, Diagnostics Systems Laboratories, Inc., Webster, TX) and 
estradiol (E2) (Coat-A-Count Estradiol, Diagnostic Products Corporation, Los Angeles, CA) 
were measured for females. 
Protocol 
All vascular tests began between 0700-0830, and were performed in a quiet, temperature-
controlled room.  Participants refrained from alcohol and exercise for 24 hours and caffeine for 
12 hours and were fasted or had consumed a very low-fat, snack prior to coming to the lab.  
Vascular measurements were taken during rest (1 min.), occlusion (5 min.) and during PORH 
(2.5 min.) (Fig. 3.1a).  Complete occlusion of the brachial artery was accomplished by rapid 
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inflation of a pediatric blood pressure cuff to > 250 mm Hg, just proximal to the antecubital fossa 
(distal to the BA imaging).  Three trials were obtained for each subject with > 10 min. between 
for vessel recovery.  Accepted trials (see below) were averaged before analysis for BA and 
microcirculatory responses for each subject. 
Vascular Function Tests 
Subjects lay supine with the right upper limb extended laterally at heart level, and slightly 
supinated for the duration of the trials.  The brachial artery was imaged as far proximal as 
possible to the antecubital fossa, to avoid a potential high origin of the radial artery (a common 
anomaly documented in at least 12.5% of people (8) and noted in 3 of our subjects).  To maintain 
the ultrasound image and measurement position, the arm was secured in a wooden foam lined 
frame and the probe was secured with a stereotactic clamp.  This allowed minor adjustments to 
be made to produce a simultaneous optimal blood velocity signal and vessel image, yet also 
insured all trials for a given subject were measured from the same 10 mm section of the artery.  
BA blood velocity was measured with pulsed Doppler ultrasound (GE VIVID3, GE Medical 
Systems), with an integrated packaged ECG and a 10L linear array transducer.  The BA was 
imaged with the same probe at 8-MHz in 2-D B mode. Discontinuous longitudinal BA images 
and beat-by-beat velocity tracings (three at rest, one during the last minute of occlusion, and at 5, 
10,15 s post-occlusion, and an additional ten at exactly 10-15 s intervals for the remainder of 
post-occlusion) were obtained, coded, and stored on the ultrasound hard drive.   
Skeletal muscle oxygenation was evaluated continuously during the protocol using 
Frequency-Domain MultiDistance Near-infrared Spectroscopy (OxiplexTS, Model 96208, ISS, 
Champaign, IL, USA) system operating at wavelengths of 692 and 834 nm with a modulation 
frequency of the light-source intensity of 110 MHz. The probe utilized source-detector 
separations of 2.0, 2.5, 3.0 and 3.5 cm. FDMD NIRS provides measurement of absolute 
concentrations (in μM) utilizing continuous dynamic measurement of reduced scattering 
coefficients (μ’S, cm-1) and thus can provide quantitative measures of hemoglobin (Hb) 
/myoglobin (Mb) oxygenation states.  The signal emanates from the microvasculature since in 
vessels larger than ~1mm there is a large amount of absorption of light (25).  Because of similar 
spectral characteristics it is not possible to distinguish between hemoglobin and myoglobin 
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contributions to the signals. Thus, even though there is myoglobin contribution to the signal the 
variables reported were deoxy-hemoglobin ([HHb]) and oxy-hemoglobin ([HbO2]).   
The probe was positioned longitudinally on the lateral anterior antebrachium overlying 
flexor digitorum superficialis, flexor carpi radialis and brachioradialis.  It is generally accepted 
that the region of maximal sensitivity will be found between, and below the surface of the skin at 
a depth of roughly half the distance between the source and detector (31). Ultrasound images 
were taken at the same location as the NIRS probe in order to accurately access underlying ATT.  
The change in [HHb] during arterial occlusion was used to estimate forearm muscle oxygen 
consumption, while the change in [HbO2] during post occlusive reactive hyperemia was used as 
an indicator of changes in perfusion, predominately of forearm skeletal muscle, and downstream 
compliance of the arterioles, capillaries and venules.  Total hemoglobin ([THb]) was determined 
as the sum of [HHb] and [HbO2]).  Tissue O2 saturation (StO2) was calculated as StO2 = [HbO2] / 
THb (%).  The NIRS data were stored at an output frequency of 31.25 Hz.   
BA diameter, velocity, and blood flow 
Trials were excluded for poor or missing critical BA images, weak velocity signals or 
venous contamination of the velocity signals.  Examinations of the BA images were performed 
in random order, by a single sonographer blinded to the subject identification.  BA diameter was 
measured on frozen images with electronic calipers as the anterior to posterior endothelial-lumen 
interface and determined from an average of 3 successive cardiac cycles, 3 measurements / 
cardiac cycle, both for the widest diameter (caused by the systolic pressure wave, coincident with 
the T wave on the electrocardiogram) and narrowest diameter (caused by diastolic pressure, 
coincident with the end of QRS on the electrocardiogram).  One trial for one subject was 
randomly chosen and blindly measured on 5 separate days to determine the reproducibility of 
ultrasonographer assessment of BA diameters. The average coefficient of variation for 18 
measurements was 0.82%, range 0.42%-1.79%.  Due to the visually large fluctuations between 
systolic and diastolic diameters in a number of subjects, mean vessel diameter was calculated as 
diastolic diameter + 1/3(systolic-diastolic diameter).  Average velocity per cardiac cycle was 
calculated by the manufacturer’s software.  Brachial artery blood flow (BABF), for any time 
point, was calculated as average velocity x π(average diameter/2)2.  Parameters to describe the 
BABF PORH response were:  R (baseline during resting conditions), y1 (baseline for the last 30 
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s of the cuff occlusion), K (the amplitude of the PORH response from y1), K’ (the amplitude of 
the PORH response from R) and 95 s (the blood flow above R, 95 seconds after cuff release). 
Forearm skeletal muscle metabolic rate 
Arterial occlusion produces a closed vascular compartment, where the rate of increase in 
[HHb] represents the rate of oxygen extraction/utilization, which is VO2.  This is true as long as 
[THb] remains relatively constant.  To control for this, trials were excluded in which [THb] 
increased > 15% of the baseline value during the 5 min. occlusion. Data for 3 of the 26 subjects 
were excluded based on this criteria.  Muscle oxygen uptake or metabolic rate (MR) was derived 
from NIRS by taking the slope of the initial linear increase in HHb ([HHb]/s) (Fig 1b).  
Concentration changes were expressed in μM/s and converted to MR expressed as micromoles 
O2 per 100 grams of tissue per minute (μmol O2 / min / 100 g). A value of 1.06 g/ml was used 
for muscle density (38) and 1:4 as the molecular ratio between hemoglobin and oxygen. 
Kinetics of PORH tissue perfusion 
The reappearance of oxygenated blood after cuff release should mostly reflect perfusion.  
Thus, microcirculatory reactivity was assessed by the kinetic response of [HbO2] during the 
initial phase of PORH.  The 3 trials were averaged for 20 s prior to and 60 s after cuff release.  
The average response was modeled using best fit for the data with a single logistic model with no 
time delay (Fig. 3.1c).   
Y = y1 + _________K________ 
        1 + e (-ln (81) x (t-tm)/d) 
Where y1= [HbO2] at the end of cuff occlusion, tm=the time to midpoint of the PORH response 
and d=the time between 10% and 90% of the response.  Intrasubject coefficients of variation 
(CV) for the curve-fitting parameters for the 3 individual trials  were determined for 5 subjects.  
Average CV for y1 = 4.7% (range 1.2 – 10.3), K = 6.7% (range 2.4 – 13.2), tm = 9.7% (range 6.5 
– 16.5), and d = 13.4% (range 3.3 – 25.5). 
To test the hypothesis that the NIRS [HbO2] signal reflects the microcirculatory response 
most closely reflective of perfusion during PORH, we compared the parameters describing this 
response with the same parameters of an independent method, BABF, which has previously been 
used to describe the microcirculatory response (26, 37).  The reduced temporal resolution of the 
 46
BABF response precluded accurate assessment of the time based parameters determined for 
[HbO2] (i.e., Tm and d); thus, only amplitude parameters (R, y1, K and 95s) were compared.  In 
general, descriptors of the amplitude of the response (e.g. K, 95s) are referenced to y1.  When 
these are referenced to the resting value (R) they are denoted as K’ and 95s’. 
Statistics 
All numerical values are presented as mean + SD unless otherwise indicated. Pearson 
product moment correlation analysis was performed to assess significance of relationships 
between variables.  Statistical analysis was performed using SigmaPlot 2001 (version 7, San 
Jose, CA, USA).  Significance was declared for relationships whose correlation coefficient 
exceeded that required for P<0.05 (Dixon and Massey, Table A.30). 
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Results 
Subject Characteristics 
Subject characteristics are presented in Table 3.1.  Gender was equally distributed in this 
young (21.6 + 2.1 yrs) cohort. All subjects were normotensive.  Two subjects were determined to 
be “overweight” (BMI 25-29.9), and two subjects were “obese” (BMI 30-34.9).  The remaining 
19 subjects were “lean” (BMI < 25). 
Importance of Correcting NIRS Parameters for ATT 
All of the [HbO2] amplitude parameters (R,y1, K [as K, K %y1, K’, and K’ %R], and the 
values at 95 s [95s, 95s %R, 95s %y1]) were significantly correlated with MR (P< 0.05 to 
0.0001).  However, the same [HbO2] amplitude parameters were also significantly correlated 
with ATT.  In turn, MR was also highly significantly correlated (r=0.77, P<0.0001) with ATT 
(Fig. 3.2).  Therefore, each [HbO2] parameter was corrected for the variation in signal amplitude 
introduced by skin and fat pad thickness (designated by “subscript c”) by utilizing the slope of 
the linear relationship between each parameter and ATT.  The same correction was made for the 
influence of ATT on MR (MRC) (Fig. 3.2).  Fig. 3.3 exemplifies the importance of correcting 
NIRS parameters for ATT is exemplified.  Both the amplitude of the initial hyperemic response 
(K) and the amplitude  at 95 s in recovery as a % of the end cuff value (y1) were significantly 
correlated with the uncorrected MR.  Both of these parameters were also highly significantly 
correlated with ATT (P<0.0001 and P<0.002 respectively).  However, when MR and these 
parameters were corrected for ATT (KC and (95s %y1)C respectively), KC remained highly 
significantly correlated with MRC (P<0.001) while (95s %y1)C was not correlated with MRC 
(P>0.05).  These findings emphasize the necessity to correct NIRS signals for ATT in order to 
accurately assess true physiological relationships between variables.  When corrections were thus 
applied, MRC was significantly correlated with [HbO2]. 
Forearm Skeletal Muscle Metabolic Rate 
As seen in Fig. 3.2, forearm skeletal muscle metabolic rate when uncorrected for ATT 
was 1.70 + 0.86 μMO2/min/100g but with an almost 7-fold range (0.52 – 3.60 μMO2/min/100g).  
However when corrected for ATT, MRC averaged 4.66 + 0.68, with a 1.9 fold range (3.42-6.48 
μMO2/min/100g). 
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Comparison of two measures (NIRS [HbO2] and BABF) of the PORH microcirculatory 
response 
Fig. 3.4 shows [HbO2], [THb], and BABF during PORH for two subjects with different 
kinetic responses while the mean responses and kinetic parameters are presented in Table 3.2.  
Fig 3.5 shows relationships between the amplitudes (K) of the response, for [HbO2] and BABF, 
whether related to end cuff (%y1) or to rest (%R). These two measures of microcirculatory 
response were significantly correlated but only after correction for ATT (r=0.52, P<0.01); 
r=0.39, P<0.04 respectively).  These results underscore once again, the importance for correcting 
NIRS amplitude measures for ATT.   
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Discussion 
There are several unique aspects to the present study:  To our knowledge, this is the first 
report (a) to model the time course of  [HbO2] using NIRS in healthy subjects during PORH, (b) 
to demonstrate the necessity for correcting these [HbO2] responses for ATT, (c) to correlate these 
with forearm skeletal muscle metabolic rate, and (d) to compare these responses with 
corresponding brachial artery blood flow responses as an independent assessment of 
microcirculatory reactivity.  The major findings of the present study are: (1) [HbO2] at rest was 
highly correlated with MR, (2) [HbO2] at end cuff occlusion was negatively correlated with MR, 
(3) the amplitude of the initial [HbO2] response, but not the time course, was significantly related 
to MR, and (5) the scaled amplitudes of the initial [HbO2] response, but not the time course nor 
the amplitude in recovery, were correlated with the corresponding BABF parameters. 
Importance of Correcting NIRS signals for ATT 
Adipose tissue influences NIRS light propagation such that true [Hb] and [HbO2] will be 
underestimated if ATT is not taken into account (14).  ATT in the present study was variable 
(range 2.48-7.30 mm) and generally low for these predominantly lean (83%) subjects.  Even with 
this low range of ATT, however, muscle MR, as well as the amplitude parameters for [HbO2], 
were negatively correlated with (i.e. impacted by) ATT.  Yang et al. in (2005) found that optical 
coefficients attributed to fat could be ignored if the fat thickness was less than 5 mm (41).   Van 
Beekvelt et al. (35) found no correlation between ATT and forearm muscle MR but their subjects 
had a very narrow range of ATT, well below the 5 mm cut-off (mean 2.2 + 0.08mm).  Consistent 
with these observations was that forearm MR was not significantly correlated with ATT for 
subjects with ATT < 5mm (r = 0.06, P> 0.05) but was for subjects with ATT > 5 mm (r = 0.79, 
P< 0.003) (Fig. 3.2).   
Van Beekvelt et al. (33), utilizing continuous wave NIRS and skin caliper ATT 
measurements, determined upper and lower values for forearm skeletal muscle MR relative to 
ATT and proposed that subjects with different ATT could be compared by normalizing the data 
to ATT.  Following the same rationale, MR and all [HbO2] amplitude parameters in the present 
study were corrected for ATT.  As seen in Fig. 3.2, without correction there was a significant 
decrease in apparent muscle MR with increasing ATT, and accurate physiologic measures of 
forearm skeletal muscle MR were suspect as there was ~7-fold range in the data, similar to the 
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10-fold range of MR seen by Van Beekvelt et al.(33).  In comparison, when corrected for ATT, 
there was a ~ 2-fold range in forearm skeletal muscle metabolic rate in the present study (Fig. 
3.2), which is less than the that associated with direct Fick method determination of forearm MR 
(3, 36). 
The variability imposed by ATT on MR, as well as on the [HbO2] signal, also resulted in 
erroneous correlations between MR and parameters of the [HbO2] response (Fig. 3.3).  The 
validity of using NIRS to assess the microcirculatory response is also contingent on corrections 
for ATT.  When uncorrected, none of the NIRS [HbO2] parameters were significantly correlated 
with the BABF parameters (Fig. 3.5 top panels) but the corrected amplitudes for [HbO2] were 
significantly correlated with the corresponding BABF parameters (Fig. 3.5 bottom panels).  
Thus, both false significant correlations (Fig. 3.3) as well as missed significant correlations (Fig. 
3.5) were observed in the present study when ATT was not considered. 
Forearm Skeletal Muscle Metabolic Rate 
The wide range of forearm metabolic rates reported in the literature utilizing NIRS 
technology were most likely influenced by the range of ATT in the subjects, but there are a 
number of other reasons why comparison of the values in the present study with those reported in 
the literature may be untenable.  
In the present study [THb] provided verification whether or not blood was not 
accumulating under the probe during cuff occlusion.  Even at cuff pressures of 250-300 mm Hg, 
9 of the 75 trials (12%) had > 15% increase in [THb] during cuff inflation and were thus 
excluded.  Few studies have reported excluding trials in which [THb] did change (10, 35). In 
contrast, two studies have reported 30-60 s for cuff inflation to achieve arterial occlusion (23, 
24), which likely were associated with large increases in [THb]. 
MR at rest has been measured in the forearm using NIRS with either venous or arterial 
occlusion protocols.  One advantage of venous occlusion is that forearm blood flow can be 
estimated concomitantly (10, 13, 19, 36).  MR obtained during venous occlusion has been found 
to agree with (10) or underestimate by half (13) values obtained without occlusion.  Poor 
reproducibility (CV of 33%) led Van Beekvelt, M. C. et al. (35) to conclude that the venous 
occlusion method does not provide a reliable quantitative value for MR. 
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On the other hand, estimating MR from NIRS using the arterial occlusion method has 
shown to be reproducible (8).  Supra-systolic tourniquet-induced ischemia was first utilized by 
De Blasi, R.A. et al. (12).  They derived MR by calculating the rate of conversion of HbO2 to 
HHb (U[Hb diff]) during the first 60 s of the linear decrement during the cuff occlusion.  
Subsequent reports have used the same method (10, 11, 13, 36).  However, the U[Hb diff] 
calculation of De Blasi et al. (12) in reality sums the rates of change of both [HbO2] and [HHb] 
with the net effect of an overestimation of MR by a factor of two.  In contrast, the present study 
defined  MR  as  the rate of appearance of HHb (U[Hb]) (Fig. 3.1b) during the initial linear 
increase following the cuff occlusion/inflation. The Hb desaturation rate under these conditions 
seems a more appropriate measure of MR.  While there is wide variability in reported values for 
the studies above for NIRS arterial-occlusion-derived MR, the averages are indeed over twice as 
high [(4.96 + 0.76 (12), 2.7 + 0.04 (11), 3.45 + 0.98 (13), 2.9 + 0.09 (10), 4.91 + 1.34 (36), 
overall AV 3.78 + 0.64 μMO2/min/100 g)] when compared to the present study (mean 1.70 + 
0.86 μMO2/min/100g) (all values uncorrected for ATT).  If corrected for ATT, presumably all of 
the previous measurements would remain ~ twice as high as the present data. 
Previous studies of human forearm reported VO2 at rest to be 4.4 + 1.3 μMO2/min/100g 
(27), 5.8 + 3.9 μMO2/min/100g (18) and 6.7 + 2.7 μMO2/min/100g (35)  based on direct Fick 
method (Av 5.6, range of averages 4.4 – 6.7 μMO2/min/100g).  The MR reported in the present 
study (4.66 + 0.68, range 3.42 – 6.48 μMO2/min/100g) is close to these previous findings based 
on direct measurement of muscle oxygen uptake (N.B. In two studies, NIRS-determined oxygen 
uptake of forearm flexor muscles has not correlated with measurements of muscle MR by direct 
Fick method (3, 36)). 
Influence of metabolic rate on [HbO2] responses 
The NIRS [HbO2] signal is a measure of oxygenated hemoglobin within a tissue volume 
and changes in the signal are presumably influenced by both arterial inflow and MR ([HbO2] = 
[THb] – [HHb]).  At rest with intact circulatory flow, we found that [HbO2] at rest was 
significantly correlated to MR. During occlusion, with cessation of blood flow, the forearm 
becomes a closed vascular compartment and the [HbO2] signal should only reflect O2 utilization 
(MR) (2 in Fig. 3.1 panel b).   Indeed, the amount of O2 remaining in HbO2 at the end of 5 min. 
of ischemia inversely corresponded to the metabolic rate of the tissue (P<0.01).   
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During the initial PORH response, we envisioned that [HbO2] would be primarily 
influenced by changes in perfusion (3 in Fig. 3.1 panels b and c) and that parameters describing 
the magnitude of the response should correspond to the putative quantity of vasodilators released 
by the ischemic tissue which, in turn, would reflect the metabolic rate of that tissue. Indeed, we 
found the amplitude of the hyperemic response scaled either from end cuff or from rest, was 
highly significantly correlated with MRC (P<0.0001 and P<0.001 respectively), as hypothesized.  
However, none of the parameters describing the time course, either of the initial response or in 
recovery, were correlated with MR despite a large range for the PORH [HbO2] time responses 
for subjects (Table 3.2). As an example, Fig. 3.4 shows the PORH response of two subjects 
where the time to midpoint of the response (tm) for one is ~1/3 that of the other. We appreciate 
that the [HbO2] signal is not a measure of absolute blood flow, but we wondered if the temporal 
profile of this signal was related to that of flow.  We presume that there is a physiologic reason 
for intersubject differences in the time course of responses, but in light of the lack of correlation 
it remains unclear as to the mechanistic determinants of the [HbO2] kinetics during PORH. 
Finally, the mechanism(s) responsible for restoring vascular tone to precuff conditions in the 
recovery phase do not seem to be determined by metabolic rate, as evidenced by the lack of 
correlation between the 95 s value and MR. 
Comparison of NIRS [HbO2] with an independent measure of microcirculatory PORH 
To validate [HbO2] as a measure of microvascular reactivity during PORH, comparisons 
were made with corresponding parameters describing BABF.  The significant correlations 
between the [HbO2] amplitude parameters and the corresponding BABF parameters gives 
credence that the amplitude of the [HbO2] response is an indicator of microvascular reactivity 
and thus, the potential utility of NIRS to noninvasively measure microvascular dysfunction. 
However, later in recovery, [HbO2] at 95 s does not correspond to conduit artery blood flow. 
Disparity between the kinetics of adjustment of [HbO2] and BABF during PORH suggest that the 
downstream distribution of flow may be multi-compartmental.  BABF is the integral of all flow 
while the vascular compartment sampled by NIRS may not reflect the sum total of all the 
forearm vasculature during the response.  Similar disparity between conduit artery and estimated 
capillary blood flow kinetics following the onset of exercise has been reported (17). 
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Study Limitations 
A number of the limitations of this study are related to the general assumptions of NIRS.  
It is assumed that Hb is the only absorbing chromophore that changes in the oxygenation signal, 
which will then reflect a change in [HbO2].  In fact, there is an unknown contribution from 
myoglobin concentration [Mb] under different conditions. Thus, total [Mb] has the potential to 
be a confounding factor to NIRS parameters measured during PORH.  However, the presence of 
myoglobin does not influence the MR calculation because changes in the light absorption 
characteristics depend on the total amount of chromophore present and whether or not each is 
associated with O2  (i.e. the utilization of four molecules of O2, either from one molecule of 
HbO2 or 4 molecules of oxy-myoglobin) are equivalent from the standpoint of their effect on 
photon absorption, the [HbO2/MbO] signal, and the calculation of oxygen uptake.  Constant 
tissue water content is also assumed with NIRS measurements.  During PORH there can be 
simultaneous changes in blood flow and volume and blood volume changes affect the tissue 
pathlength (14).  In the present study, the FDMD NIRS instrument dynamically calculated the 
scattering coefficient for each wavelength, thus providing a dynamic correction for any changes 
in the pathlength.  Capillary hematocrit increases significantly in exercise (21) and presumably 
may change as well during PORH, producing a subsequent decrease in water content and 
increase in [Hb] in the microvascular volume from which the signal is derived.  Contributions 
from skin blood flow to the signal also cannot be ruled out.  However, in the present PORH 
protocol, changes in NIRS responses due to whole body or skin heating should be nominal since 
subjects were supine, at rest, participating in a non-stressful protocol and were in a thermally 
controlled environment.  Further, source-detector separations of up to 3.5 cm should insure that a 
large proportion of the signal emanated from deeper tissue (31). 
In the present study, BABF and NIRS were used concurrently during the same protocol 
in the present study to assess skeletal muscle microvascular reactivity, with the goal of validating 
NIRS as a noninvasive tool to assess the microcirculatory function in health and disease.  The 
lack of correlation for the kinetic parameters of these two methodologies may well reflect 
comparisons that were not identical.  BABF during PORH is the total blood flow to all 
downstream tissues after a period of ischemia.  NIRS derived [HbO2] during PORH reflects the 
response of primarily one vascular bed (volume of skeletal muscle immediately under the probe) 
during the same time period.  There was a correlation between the two methodologies for the 
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amplitude of the initial hyperemic response, which may reflect the effect of hydraulics on 
conduit and local hemodynamics following cuff release. However, it is possible that the 
distribution of blood flow in the forearm during recovery may have influenced the lack of 
agreement between BABF and [HbO2] recovery amplitude (95 s values) and kinetic parameters 
(tm, d). 
Conclusion 
The main purposes of this study were to determine a robust measure of forearm skeletal 
muscle metabolic rate in resting conditions and to determine parameters of the post-occlusive 
reactive hyperemia test utilizing NIRS. Comparisons of [HbO2] parameters were made with 
brachial artery blood flow as an independent methodology to access microcirculatory reactivity.  
From the results of this study it can be concluded that NIRS is a useful noninvasive tool for 
investigating tissue metabolism and microvascular reactivity. Strong evidence was provided for 
the imperative to correct NIRS signals for the effects of subcutaneous fat.  We found that end-
cuff values for [HbO2] were inversely correlated with metabolic rate.  Further, the amplitude of 
the PORH response for [HbO2] was correlated with metabolic rate (i.e. the higher the metabolic 
rate, the greater the PORH [HbO2] response).  The [HbO2] amplitude also correlated with that of 
brachial artery blood flow, suggesting that the amplitude of the PORH response in the 
microcirculation was similar to that in the conduit artery.  However, neither the [HbO2] 
parameters describing the time course of the initial response nor in recovery were correlated with 
metabolic rate or with brachial artery blood flow.  Further studies are warranted to evaluate the 
potential use of NIRS to monitor tissue microvascular responses during PORH in assessing 
disease states, the affects of disease on oxygen transport, and utilization and the efficacy of 
therapies for microvascular pathology. 
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Tables 
 
Table 3.1 Subject Characteristics 
 
Subject Characteristics n=23 
Gender (female / male) 12/11 
Age (yr) 21.6 + 2.1 
Height (cm) 175 + 10 
Weight (kg) 73.3 + 17.6 
Resting heart rate (bpm) 65.9 + 8.4 
Systolic BP (mmHg) 119 + 8.5 
Diastolic BP (mmHg) 71.9 + 7.3 
Waist circumference (cm) 81.0 + 13.0 
Waist-hip ratio 0.79 + 0.08 
BMI (kg/m2) 23.6 + 3.7 
Total fat mass (%) 27.6 + 8.3 
Abdominal fat (%) 34.7 + 9.9 
Fat free mass (kg x 102) 505 + 11.6 
 
Values are absolute numbers or mean + S.D. 
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Table 3.2 Values for amplitude and kinetic parameters of [HbO2] and  brachial artery  
blood flow prior to and during post occlusive reactive hyperemia. 
 
 [HbO2] amplitude parameters  BA blood flow 
 n = 21 n = 23 
y1C 54.3 + 4.5 3.28 + 2.58 
KC 68.9 + 6.6 79.7 + 32.0 
(K %y1)C  152 + 18 315 + 167** 
RC  94.1 + 7.3 10.3 + 7.3  
K’C  24.6 + 2.5 67.5 + 24.2 
(K’ %R)C  30.7 + 3.6  88.2 + 55.2* 
(95s)C 16.3 + 2.6 17.0 + 10.3 
(95s %R)C 19.1 + 3.9 18.2 + 66.0 
(95s %y1)C 33.9 + 5.7 74.9 + 48.2 
 [HbO2] kinetic parameters  
tm (s) 11.7 + 4.0 ---- 
d (s) 22.0 + 8.0 ---- 
tm + 0.5d 22.7 + 7.5 ---- 
 
Amplitude parameters of [HbO2] (μM) corrected for adipose tissue thickness, and brachial artery 
(BA) blood flow (cm3/s).  Values at y1=end cuff, K=amplitude from end cuff, R=rest, K’= 
amplitude from rest, and 95s= amplitude from rest at 95 s.  Values for [HbO2] kinetic parameters 
(s) for tm (time to midpoint of the post occlusive reactive hyperemia (PORH) response), d (time 
between 10% and 90% of the PORH response). Significant correlations occurred between BA 
blood flow and corrected [HbO2] amplitude parameters at *P<0.03 and **P<0.01. 
 
 62
 
Table 3.3 Correlations between either [HbO2]  amplitude or kinetic parameters prior to 
and during post occlusive reactive hyperemia and metabolic rate and adipose tissue 
thickness. 
 
[HbO2] amplitude parameters MR ATT [HbO2]C with MRC 
y1 P<0.0001 P<0.0001 P<0.01 
K P<0.0001 P<0.0001 P<0.0001 
K %y1 P<0.0001 P<0.0001 ns 
R P<0.0001 P<0.0001 P<.0001 
K’ P<0.0001 P<0.0002 P<0.001 
K’ %R P<0.004 P<0.005 Ns 
95s P<0.0001 P<0.0002 Ns 
95s %R P<0.05 P<0.05 Ns 
95s %y1 P<0.004 P<0.002 Ns 
    
[HbO2] kinetic parameters    
tm  ns ns Ns 
d  ns ns Ns 
tm + 0.5d ns ns Ns 
 
[HbO2]  amplitude (μM) or kinetic parameters (s) (column 1) prior to and during PORH and 
metabolic rate (MR) (μMO2/min/100g) (column 2) and adipose tissue thickness (mm) (ATT) 
(column 3).    Values at y1=end cuff, K=amplitude from end cuff, R=rest, K’= amplitude from 
rest, and 95s= amplitude from rest at 95 s. Correlation between [HbO2] parameters corrected for 
ATT (subscript c) and MR corrected for ATT (subscript c) (column 4). ns = non-significant. 
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Figures 
Figure 3.1 [HHb] and [HbO2] at rest, during occlusion, and during post occlusive reactive 
hyperemia in one subject. 
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(Panel a)  Three individual trials in one subject showing high reproducibility of [HHb] at rest (1 min), 
during occlusion (5 min) and during post occlusive reactive hyperemia (PORH) (2.5 min).  (Panel b) 
Average of three trials of [HHb] (gray line) and [HbO2] (black line).  Initial linear increase in [HHb] (dark 
gray) used to determine forearm skeletal muscle metabolic rate (MR).  (Panel c) Single logistic model of 
the average of three trials for [HbO2], 30 sec prior to end cuff and 60 sec during PORH.  Parameters of 
the response are R (rest), y1 (end cuff), K (amplitude from y1), K’ (amplitude from R), tm (time to 
midpoint), d (time between 10% and 90% of the response) and tm + 0.5d (estimate of the peak of the 
response).  See text for further details. 
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Figure 3.2 Forearm metabolic rate as a function of adipose tissue thickness. 
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Forearm metabolic rate (MR) as a function of adipose tissue thickness ATT uncorrected (open 
circles) and corrected (filled triangles) for adipose tissue thickness (ATT).  Uncorrected MR (Av 
= 1.70 + 0.86, Range 0.52 – 3.60 μMO2/min/100g) (6.9x range).  Corrected MR (MRC) (Av = 
4.66 + 0.68, Range 3.42 – 6.48 μMO2/min/100g)  (1.9x range). 
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Figure 3.3 Amplitude Amplitude of the [HbO2] post occlusive reactive hyperemia response 
and value at 95 s as a % of end cuff as functions of the metabolic rate and adipose tissue 
thickness 
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Amplitude of the [HbO2] post occlusive reactive hyperemia response (K) and value at 95 s as a 
% of end cuff  (95s %y1) as functions of the metabolic rate (MR) (top panels) and adipose tissue 
thickness (ATT) (middle panels) showing significant relationships.  However, when K and 95s 
%y1 are corrected for ATT (subscript c, lower panels), only KC remains significantly related to 
MR corrected for ATT (MRC). 
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Figure 3.4 te[HbO2], [THb] and brachial artery blood flow at rest, end cuff and for 2.5 min 
of post occlusive reactive hyperemia in two subjects. 
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[HbO2] (μM) (black line), [THb] (μM) (lt gray line) and brachial artery blood flow (dk gray fill) 
(cm3/s) for 2.5 min of post occlusive reactive hyperemia (PORH) after cuff  occlusion release 
(Time = 0) in two subjects.  Parameters at rest (R) and end cuff (y1) are shown for [THb] (lt gray 
circle), [HbO2] (black circle) and brachial artery blood flow (dk gray triangle). 
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Figure 3.5 Comparison of two measures of the post occlusive reactive hyperemia 
microcirculatory response. 
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Comparison of brachial artery (BA) amplitudes from end cuff (K) and from rest (K’) of initial 
post occlusive reactive hyperemia response (PORH) with that of [HbO2] in the forearm.  
Uncorrected (upper panels) and corrected (lower panels) for adipose tissue thickness (ATT).  
%y1, scaled to end cuff value.  %R, scaled to rest value.  Only the corrected [HbO2] parameters 
are significantly correlated with the corresponding brachial artery blood flow parameters. 
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CHAPTER 4 - Reduced Macrovascular Reactivity and 
Microvascular Control Abnormalities Relative to Insulin Resistance 
in Normoglycemic College-age Subjects with a Family History of 
Type 2 Diabetes 
 69
Abstract 
Objective—There are virtually no data regarding the prevalence of endothelial and 
microvascular dysfunction relative to the magnitude of early insulin resistance (IR) in 
normoglycemic, college-age adults with a genetic susceptibility for type 2 diabetes.  Thus, the 
goals of this study were to determine for a range of IR in normoglycemic, college-age adults 
with a family history of type 2 diabetes; (1) post-occlusive reactive hyperemia (PORH) flow-
mediated dilation (FMD) of the brachial artery (BA) as a measure of macrovascular 
vasoreactivity, (2) parameters describing both near-infrared spectroscopy (NIRS) and BA blood 
flow (BF) responses to PORH as indices of skeletal muscle microvascular reactivity, and (3) the 
relationship between macro- and microvascular reactivity. 
 
Research Design and Methods- Twenty-six, young (18-26 years), normoglycemic subjects 
were assessed for hepatic insulin sensitivity (ISIHOMA) and whole body insulin sensitivity 
(ISICOMP) by measures of plasma glucose and insulin both in fasting conditions and during an 
oral glucose tolerance test (OGTT).  Each subject underwent three trials of upper limb PORH 
while BA velocity and  were determined by Doppler ultrasound and changes in forearm oxy- 
(hemoglobin/myoglobin) ([HbO2]) and deoxy- (hemoglobin/myoglobin) ([HHb]) were 
determined by NIRS.  Forearm skeletal muscle metabolic rate (MR) was estimated from the 
initial linear decrease in [HHb] during the cuff occlusion.  Endothelium-dependent 
macrovascular reactivity was determined by peak % change in BA diameter standardized by the 
area under the curve shear rate stimulus. The PORH [HbO2] responses were modeled and 
parameters describing amplitude and the time course of the response were determined..  The 
same parameters describing the BABF response were determined, as a second independent index 
of microvascular reactivity. 
 
Results—Subjects exhibited a 5-fold range in ISICOMP (9.88 + 3.98, range 3.6-18.5) and 54% 
were IR (ISICOMP < 9.7).  Decreasing ISICOMP (increasing IR) was negatively correlated with % 
change in BA diameter (r =-0.49, P<0.01).  Microvascular reactivity, as measured by [HbO2] 
parameters, was not significantly different between IR and insulin sensitive (IS) subjects while 
most BABF amplitude responses were significantly different between IR and IS.  Additionally, 
increasing ISICOMP was significantly negatively correlated with BABF at rest and the hyperemic 
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response from end cuff (r=-0.48, P<0.01 and r=-0.43, P<0.03 respectively).  This enhanced BF 
relative to IR was not correlated with mean arterial pressure, but was correlated with an increase 
in conductance at rest, at peak hyperemia and at 95 s (P<0.01, P<0.04, P<0.01 respectively). 
Parameters of BABF (microvascular response) at rest, peak hyperemia from rest, at 95 s PORH 
and total hyperemic response were significantly negatively correlated with % change BA 
diameter (macrovascular response) (all P<0.04). 
 
Conclusions—The present study demonstrated that IR in otherwise healthy, normoglycemic, 
college-age subjects with a family history of type 2 diabetes is associated with both early macro- 
and microvascular dysfunction. 
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Introduction 
Macro- and microvascular disease are the leading causes of morbidity and mortality in 
patients with type 2 diabetes (21).  Endothelial dysfunction is incidental to macrovascular disease 
and predictive of cardiovascular events (12, 80), and has been linked to a decrease of the 
bioavailability of nitric oxide (NO).  Since NO is a potent antiatherogenic molecule, it is 
believed to be a main mechanistic link between attenuated macrovascular reactivity and 
concurrent macrovascular pathology.  Under specific conditions, brachial artery (BA) flow-
mediated dilation (FMD) is almost entirely mediated by NO (58).  BA FMD is an independent 
predictor of future cardiac events (80), correlated with coronary vasomotor dysfunction and may 
be useful for early detection of coronary artery disease (5). 
     In the natural history of type 2 diabetes, metabolic and physiologic changes begin 
early and proceed in tandem (49).  However, even though this process is exacerbated by, it is not 
dependent on, hyperglycemia.  This association is corroborated by the conclusion that insulin 
resistance (IR) in young adults predicts coronary heart disease risk factors (4) and is an 
injunction that the progress of cardiovascular complications and silent atherosclerosis can hide 
behind a façade of “health”, particularly in young adults.  IR can be detected in young adult, 
nondiabetic offspring of type 2 diabetic parents (67, 73).  The few prior studies that have 
examined endothelial-dependent macrovascular dysfunction in normoglycemic subjects included 
those that ranged in age between the late 20s and old age.  However, for the vast majority of 
literature involving BA FMD, the response is not standardized by the magnitude of the stimulus 
that mediates the response even though there is compelling justification to do so (46, 56-58).   
Microvascular complications are frequent in diabetes, as evidenced by the fact that  ~62% 
of diabetic patients will have retinopathy in the course of their disease (86).  Retinal and renal 
microangiopathy cause diabetic retinopathy and nephropathy respectively, and the 
microangiopathy of the vasa nervosum contributes to the pathogenesis of neuropathy.  The 
literature taken together is unequivocal that impaired microvascular reactivity is clearly present 
in diabetes and prediabetes, but there is sparse information that predates dysglycemia in the 
continuum toward frank disease and these few studies have utilized acetylcholine or local 
heating to evaluate cutaneous microcirculatory responses.  These studies may not necessarily be 
relevant to control of the microcirculation in skeletal muscle.  We propose to utilize two non-
invasive methods to determine changes in downstream microvascular reactivity in skeletal 
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muscle during post-occlusive reactive hyperemia (PORH):  BA blood flow (BF) (using duplex 
Doppler ultrasound) and forearm tissue oxygenation (using frequency domain multi distance 
(FDMD) near infrared spectroscopy (NIRS)).    
We hypothesize that in normoglycemic, college-age students with a family of type 2 
diabetes; (1) macrovascular dysfunction, measured by BA FMD, after correction by the shear 
rate (SR) stimulus, will be diminished relative to the magnitude of IR, (2) parameters for BABF 
and for FDMD NIRS will be attenuated relative to the magnitude of IR, and (3) parameters 
describing macrovascular reactivity (FMD) will correlate with corresponding parameters for 
microvascular reactivity (BABF and NIRS). 
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Methods 
Subjects and exclusion criteria 
Twenty-six healthy, sedentary, college-age subjects (13 men, 13 women), age 18-26 yrs., 
participated in this study.  Twenty individuals were self-reported first-or second-degree relatives 
of patients with type 2 diabetes (had family history (FH)) and 6 were of similar BMI and gender 
distribution with no known family history of type 2 diabetes (no FH). Three of the FH subjects 
were siblings (2M, 1F).  To minimize confounding factors for insulin sensitivity and/or 
vasoreactivity, potential subjects were excluded if they had a history of smoking, regular 
exercise in the last 6 months of > 3x20 min. sessions/week of at least moderate intensity aerobic 
exercise, or had self-reported medical conditions of Acanthosis Nigricans, polycystic ovarian 
syndrome, or irregular menses with hirsutis.  Exclusion criteria also included current weight loss 
or dietary modifications, antioxidant therapies or a diet that included a combination of > 4 
servings fruit and vegetables/day or hormone therapy or hormonal contraception (except low 
dose combination ethinyl estradiol/progestin pills).  Female subjects were studied during the 
early follicular phase of their menstrual cycle as verified by progesterone (P4) levels < 1.5 ng/ml.  
Potential subjects taking antihypertensives, lipid-lowering agents, drugs to control blood sugar 
(metformin, sulfurylureas), bronchial dilators, or psychoactive medications were excluded.  On 
the day of screening subjects were excluded if 12 hr. fasting glucose levels were > 100 mg/dl, as 
measured by a hand held glucometer (FreeStyle Flash, TheraSense, Alameda, CA) or if blood 
pressure was > 140/95 mmHg.  Data were rejected if measurements on subsequent days included 
results above the cut-off for exclusion as enumerated for the initial screening, or if biochemical 
analysis indicated triglycerides levels > 300 mg/dl, cholesterol levels > 210 mg/dl or 2 hr. post 
OGTT > 140 mg/dl.  Four subjects, from an initial 30 screened, were excluded.  Three subjects 
were overweight (OW) (BMI, 25-29.9 kg/m2), three subjects were obese (O) stage 1 (BMI, 30-
34.9 kg/m2), and one subject was obese stage 2 (BMI > 35 kg/m2).  Nineteen lean subjects (L = 
BMI < 25) were included.  All were recruited from the general population of students at Kansas 
State University.  Informed consent was obtained after both written and verbal explanation about 
the possible risks and discomforts of the experimental protocol were given.  The study was 
approved by the Institutional Review Board for Research Involving Human Subjects at Kansas 
State University. 
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Oral Glucose Tolerance Test (OGTT) and analytical procedures 
Subjects reported to the lab between 0700-0800 after a 10-12 hour fast and 24 hour 
abstinence from any exercise, alcohol and caffeine for a 2-hour oral glucose tolerance test 
(OGTT).  An indwelling antecubital catheter was inserted and kept patent with a continuous 
isotonic saline drip.  Subjects rested at least 15 min. before the initiation of the test.  Baseline 
blood values were collected for fasting serum glucose (FG) and fasting serum insulin (FI) at -15, 
-10, and -5 min. and the mean of the 3 results was used as the baseline blood sample. Subjects 
then ingested 1.75 g of glucose (SUN-DEX 10 g. glucose/fl. oz.) per kg body weight and timing 
of the test was referenced to the beginning of the drink (t=0) with subjects having <5 minutes to 
completely consume the drink. Additional samples were then drawn at t=30, 45, 60, 75, 90 and 
120 min.  All samples were collected in serum separating tubes and the serum separated using 
refrigerated centrifugation at 3,000 rpm for 10 min.  Samples were immediately analyzed for 
serum glucose (mg/dl) (YSI 2300 glucose oxidase analyzer).  Serum insulin (μU/ml) was stored 
in liquid nitrogen and measured later by monoclonal, two-site, immuno-radiometric assay 
(Mercodia Insulin ELISA, ALPCO Diagnostics, Windham, NH) with detection limit < 1 μU/ml 
and intra assay CV < 5%.  
Anthropometry 
Measurements of height (cm), weight (kg), waist and hip circumference (cm), BMI, 
blood pressure and resting heart rate were taken.  Body composition was assessed by dual-energy 
X-ray absorptiometry (Prodogy, General Electric v. 5.6) and regions of interest were specified  
between the 7th rib and the iliac crest for measurement of visceral adiposity (abdominal fat %) 
and distal to the olecranon process for forearm skeletal muscle mass.  From a resting baseline 
blood sample, total cholesterol, HDL-cholesterol, C-reactive protein (CRP) and triglyceride 
levels were determined.  LDL was calculated from Friedewald's formula (23).  Progesterone (P4) 
(Progesterone RIA DSL-3900, Diagnostics Systems Laboratories, Inc., Webster, TX) and 
estradiol (E2) (Coat-A-Count Estradiol, Diagnostic Products Corporation, Los Angeles, CA) 
were measured for females.  Criteria for the metabolic syndrome were defined from the National 
Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III, ATP III) (20). 
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Metabolic Calculations 
Positive incremental areas under the curve (AUC-baseline) (2) during the OGTT were 
calculated with the trapezoidal method, from t=0 to 120 min, for glucose (mg/dl) (GluAUCOGTT) 
and insulin (μU/ml) (IAUC OGTT).  AUC values were divided by the 120 min. and added back to 
fasting values to determine average glucose (GluAv OGTT ) and average insulin (IAv OGTT) 
during the OGTT.  
A measurement of hepatic insulin sensitivity, ISIHOMA, was calculated as an inverse of the 
homeostatic model assessment, (44), as described by Radziuk (59), after correcting for different 
units of glucose than the original calculation. 
 
                     ISIHOMA =  FG)(FI
.
×
×18522
                       (1) 
Whole body insulin sensitivity (ISICOMP), representing a composite of hepatic and 
peripheral tissues (43), was calculated as:  
 
ISICOMP = 
000,10
)()( OGTTIOGTTGluFIFG AVAV ×××     (2) 
 
Although the present study did not validate insulin resistance (IR) in our subject cohort 
by independent means, in order to facilitate group comparisons, subjects were considered IR if 
their ISICOMP < 9.7, the upper limit of 95% ISICOMP for IR subjects as determined by impaired 
fasting glucose (IFG), reported recently by Piche et al. (52). 
Protocol 
All vascular tests began between 0700-0830 hrs, and were performed in a quiet, 
temperature-controlled room.  Participants refrained from alcohol and exercise for 24 hrs and 
caffeine for 12 hrs and were fasted or had a very low-fat snack prior to coming to the lab.  All 
vascular measurements were taken during rest (1 min.), occlusion (5 min.) and during post-
occlusive reactive hyperemia (PORH) (2.5 min.). For three of the initial subjects, blood pressure 
(BP) was continuously monitored noninvasively at the radial artery (Model 7000, Colin, TX) of 
the contralateral arm.  No changes in BP occurred prior to, during occlusion or during post 
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occlusion.  During occlusion, ischemia was induced by rapid inflation of a pediatric blood 
pressure cuff, placed just proximal to the antecubital fossa  and distal to the brachial artery (BA) 
imaging, to > 250 mm Hg.  Three trials were obtained for each subject with > 10 min. between 
adjacent tests to permit vessel recovery.  Accepted trials (see below) were averaged before 
analysis for BA and microcirculatory responses for each subject. 
Vascular Function Tests 
Standard guidelines were followed for flow-mediated dilation (FMD) of the BA in 
assessing endothelial function in a conduit vessel (15).  The mechanism for this response is the 
activation of endothelial nitric oxide synthase by shear stress and the release of nitric oxide (NO) 
resulting in FMD.  This noninvasive method was first described by Celermajer et al. in 1992 
(13).  Briefly, subjects lay supine with the right upper limb extended at heart level, and slightly 
supinated for the duration of the trials.  The brachial artery was imaged as far as possible 
proximal to the antecubital fossa, to ascertain and avoid a potential high origin of the radial 
artery (a common anomaly documented in at least 12.5% of people (8) and noted in three of our 
subjects).  To maintain the ultrasound image and measurement position, the arm was secured in a 
wooden foam lined frame and the probe was secured with a stereotactic clamp.  This allowed 
minor adjustments to be made to produce a simultaneous optimal blood velocity signal and 
vessel image.  All trials for a given subject were measured from the same 10mm section of the 
artery.  BA blood velocity and image were measured with pulsed Doppler ultrasound (VIVID3, 
GE Medical Systems) with an integrated packaged ECG and a 10 L linear array transducer 
operating at 8-MHz in 2-D B mode. Discontinuous longitudinal BA images and ~3 beat-by-beat 
velocity tracings were recorded per frame.  Three frames were obtained at rest, one during the 
last minute of occlusion, one each at 5, 10 and 15 s post-occlusion, and an additional ten frames 
at exactly 10-15 s intervals for the remainder of post-occlusion.  A total of 17 frames per trial 
were obtained, coded, and stored on the ultrasound hard drive for later analysis.  
Skeletal muscle oxygenation was evaluated continuously during the protocol using a 
Frequency-Domain Multi Distance (FDMD) Near-infrared Spectroscopy (NIRS) (OxiplexTS, 
Model 96208, ISS, Champaign, IL, USA) system operating at wavelengths of 692 and 834 nm 
with a modulation frequency of the light-source intensity of 110 MHz. The probe utilized source-
detector separations of 2.0, 2.5, 3.0 and 3.5 cm.  FDMD NIRS utilizes continuous dynamic 
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measurement of reduced scattering coefficients (μ’S, cm-1) and thus can provide quantitative 
measures (μM) of hemoglobin (Hb) /myoglobin (Mb) oxygenation states.  These signals arise 
primarily from the microvasculature since in vessels larger than ~1mm  there is a large amount 
of absorption of light (42).  Because of similar spectral characteristics it is not possible to 
distinguish between hemoglobin and myoglobin contributions to the NIRS signal.  Thus, the 
variables in the present study were reported as deoxy-[hemoglobin + myoglobin] ([HHb]) and 
oxy-[hemoglobin + myoglobin] ([HbO2]).  
The probe was positioned longitudinally on the lateral anterior antebrachium overlying 
the flexor digitorum superficialis, flexor carpi radialis and brachioradialis.  It is generally 
accepted that the volume of interrogation is found between, and below the surface of the skin at a 
depth of roughly half the distance between, the source and detector (68).  Ultrasound images 
were taken at the same location as the NIRS probe to accurately assess underlying adipose tissue 
thickness (ATT).  The change in [HHb] during the initial period of arterial occlusion was used to 
calculate forearm muscle oxygen consumption (metabolic rate (MR)), while the change in 
[HbO2] during post-occlusive reactive hyperemia (PORH) was used as an indicator of changes in 
perfusion, predominantly of forearm skeletal muscle, and downstream compliance of the 
arterioles, capillaries and venules. MR and all [HbO2] parameters used to describe PORH were 
corrected for the influence of ATT as described previously (72).  Total hemoglobin ([THb]) was 
determined as the sum of [HHb] and [HbO2]), while tissue O2 saturation (StO2) was calculated as 
StO2 = [HbO2] / THb (%).  The NIRS data were stored at an output frequency of 31.25 Hz. 
BA measurements and hemodynamics 
Trials were excluded for poor or missing critical BA images, or weak or venous influence 
on the velocity signals.  Examinations of the BA images were performed in random order, by a 
single sonographer blinded to the subject identified.  BA was measured on frozen images with 
electronic calipers as the anterior to posterior endothelial-lumen interface and determined from 
an average of 3 successive cardiac cycles, 3 measurements / cardiac cycle, both for the widest  
(caused by the systolic pressure wave, coincident with the T wave on the electrocardiogram) and 
narrowest  (caused by diastolic pressure, coincident with the end of QRS on the 
electrocardiogram).  The intraobserver coefficient of variation was 0.82% + 0.37%, range 0.42% 
- 1.79%, similar to the CVs for single observer manual analysis of 0.95-1.15% obtained by 
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Woodman et al.(87).  Due to the visually large fluctuations between systolic and diastolic 
diameters in a number of subjects, mean vessel  (BA ) per cardiac cycle was calculated as 
diastolic  + 1/3(systolic-diastolic ).  Average velocity (V) per cardiac cycle was calculated by the 
manufacturer’s software. Shear rate (SR) per cardiac cycle was calculated as V / BA  for each 
cardiac cycle. Brachial artery blood flow (BABF) per cardiac cycle was calculated as V x π( BA  
/2)2.  The data for ~ 3 cardiac cycles per frame were averaged to produce measures of BA , V, 
SR, and BABF, for each of the 17 time frames prior to and during PORH, and plotted.  
Parameters to describe the BABF PORH response were:  R (baseline during resting conditions), 
y1 (baseline for the last 30 s of the cuff occlusion), K (the amplitude of the PORH response from 
y1), K’ (the amplitude of the PORH response from R), 95 s (the blood flow above R, 95 seconds 
after cuff release) and AUC (total hyperemic response above blood flow at rest). 
Conduit endothelium dependent vasodilation 
Macrovascular reactivity was assessed as the magnitude of FMD of the BA during 
PORH.  This measure is contingent not only on the bioavailability of NO, but also the magnitude 
of the stimulus that produces the response.  Accurate shear stress measurements are difficult to 
make in vivo because velocity and viscosity measurements must be taken close to the vessel wall 
and blood flow is pulsatile.  Shear stress can be estimated by viscosity x velocity/.  It is generally 
accepted that shear rate (SR) is an adequate surrogate measure (as reviewed by Pyke, K.E. et al. 
(58) since the FMD response appears to be independent from whole body viscosity (47).  Both 
the peak and the duration of the SR stimulus has been determined to be important for the peak 
FMD response (35, 58) with the majority of the response contingent on the elevated shear 
stimulus over time (57).  Thus, in the present study BA endothelial dependent vasoreactivity was 
calculated as: 
(BA peak -BA constriction ) / BA constriction   
(% change diameter ) 
Area under the curve shear rate increase from rest for 55 s post cuff release  
(SRAUC) 
i.e. BA endothelial dependent vasoreactivity = % change diameter / SRAUC .  BA constriction was 
the smallest BA , which frequently occurred 5-10 s post cuff release. 
 79
Forearm skeletal muscle metabolic rate 
During arterial occlusion the rate of increase in [HHb] represents the rate of oxygen 
utilization, which is VO2, so long as [THb] remains relatively constant.  To control for this, trials 
were excluded in which [THb] increased > 15% of the baseline value during the 5 min occlusion. 
Muscle oxygen uptake or metabolic rate (MR) was derived from the slope of the initial linear 
increase in HHb ([HHb]/s.).  Concentration changes were expressed in μM/s. and converted to 
MR expressed as micromoles O2 per 100 grams of tissue per min (μMO2 / min / 100 g). A value 
of 1.06 g/ml was used for muscle density (37) and 1:4 for the molecular ratio between 
hemoglobin and oxygen. 
Kinetics of PORH tissue perfusion 
The reappearance of oxygenated blood after cuff release should mostly reflect perfusion.  
Thus, microcirculatory reactivity was assessed by the kinetic response of [HbO2] during the 
initial phase of PORH.  The 3 trials were averaged for 20 s prior to and 60 s after cuff release. 
The average response was modeled using a single logistic model with no time delay.   
 
Y = y1 + _________K________ 
        1 + e (-ln (81) x (t-tm)/d) 
 
Where y1=end cuff, K= amplitude from y1, tm = the time to midpoint of the response, and d = 
time between 10% and 90% of the response.  In addition, resting value (R), time to 90% peak (as 
tm + 0.5d) and amplitude from R at 95 s (95 s) were determined.      Intrasubject coefficients of 
variation (CV) for the curve-fitting parameters for the 3 individual trials were determined for 5 
subjects. Average CV for y1 = 4.7% (range 1.2 - 10.3), K = 6.7% (range 2.4 -13.2), tm = 9.7% 
(range 6.5 - 16.5), and d = 13.4% (range 3.3 - 25.5).  Finally, similar parameters as were used for 
BABF were calculated for the PORH [HbO2] response:  R, y1, K, K’, 95 s after cuff release as 
well as the total hyperemic response above resting values (AUC). 
Statistics 
All numerical values are presented as mean + SD unless otherwise indicated. One-way 
analysis of variance (ANOVA) was performed to assess significance of relationships among the 
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groups.  Correlations between variables were tested using univariate analysis by Pearson 
correlation analysis.  Statistical analyses were performed using SigmaPlot 2001 (version 7, San 
Jose, CA, USA). Significance was declared for comparisons or relationships for P<0.05 (17). 
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Results 
Subject Characteristics 
Anthropometric and clinical characteristics are shown in Table 4.1.  The male-female 
ratio for all subjects was evenly divided (13 females/13males).  Fifty-eight percent of subjects 
demonstrated IR with more males (10 of 15) being IR than females (5 of 15). Height, weight and 
systolic blood pressure (BP)  were significantly different between IS and IR (P<0.01).  The mean 
age, resting heart rate and diastolic blood pressure (BP) were not significantly different between 
IS and IR subgroups.  All subjects were normotensive (systolic BP=117 + 8 mmHg, range 96-
130 mmHg), yet systolic BP was still significantly correlated with ISICOMP for all subjects (r=-
0.46, P<0.01).    Waist circumference was significantly different between IS and IR (P<0.005) as 
was hip circumference (P<0.001, data not shown) while waist-hip ratio was not significantly 
different between the two subgroups.  BMI (P<0.005), abdominal fat % (P<0.05) and fat free 
mass (P<0.01) were significantly different between IS and IR, while total fat mass % was not. 
Blood Chemistry Measurements 
Table 4.2 shows the blood chemistry measurements for the subcategories of subjects.  No 
significant differences were seen for any serum lipid measurements or C-reactive protein 
between IS and IR subjects.  For all subjects, triglyceride/HDL ratio was significantly correlated 
with ISICOMP (r=-0.38, P<0.05).   
Metabolic Characteristics 
Metabolic characteristics in the fasted state and during the 2-hr postprandial OGTT are 
shown in Table 4.2.  None of the subjects met the clinical criteria for the metabolic syndrome 
(MS).   Three of the IS subjects exhibited one of the MS criteria (low HDL) while six IR subjects 
had at least one MS criteria, three of these had two MS criteria.  Nine of the 26 subjects had high 
levels (>3 mg/dl) of CRP and of these, one had an additional MS marker and two IR subjects had 
two additional MS markers.  FI (range 2.43-12.51 μU/ml) was within the normal range of values 
listed for the immunoassay used (range 2-25 μU/ml) yet there was a significant difference 
between IS and IR subjects  (P<0.001).  There were significant differences between IS and IR for 
all measures of OGTT insulin: IAUCOGTT (P<0.01), IAVOGTT (P<0.005), and I2HOGTT 
(P<0.05).  All subjects were normoglycemic by FG (range 69.2 - 94.6 mg/dl) and Glu2HOGTT 
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(range 61.3-124 mg/dl) clinical criteria.  However, FG was still highly significantly different 
between IS and IR (P<0.001).  IS and IR were significantly different (P<0.001) for both 
measures ISIHOMA and ISICOMP. 
Macrovascular Stimulus and Reactivity 
Macrovascular PORH stimulus and response variables are shown in Table 4.3.  There 
was a wide range of both stimulus, SRAUC, (range 260-806 s-1)) and response, % change 
diameter, (range 0.89-15.2 %).  Fig 1 shows the different shear rates and similar BA  responses 
for two subjects. However the variability in the response when standardized by the stimulus (% 
change diameter / SRAUC) was greatly reduced (range 1.44-5.05).  Fig. 4.2 shows % change 
diameter / SRAUC for two subjects .  There were no differences between IS and IR subjects for 
any of the resting or PORH SR variables.  Resting brachial artery  was significantly greater for 
IR compared to IS (P<0.02) (Table 4.3) and % change in diameter was significantly negatively 
correlated with resting  for all subjects (r=0.53, P<0.003) (Fig. 4.3).  Resting  was significantly 
greater for male versus female subjects (P<0.0001) (Fig 3) but % change in diameter failed to 
reach a statistically significance difference between genders (p=0.11) because of the large 
variability (Fig. 4.3).  However, when standardized by SRAUC, % change in diameter was similar 
between genders (P<0.95) (Fig. 4.3), and was not significantly correlated with resting  (p=0.85) 
(Fig. 4.3), nor was significantly different between IS and IR (P<0.16) (Table 4.3).  ISICOMP was 
also not correlated with resting  (r=0.21, p= 0.30) (Data not shown). 
Fig. 4.4 illustrates the importance of normalizing the % change in BA diameter to the 
stimulus.  The upper panel suggests there is no significant relationship between % change in 
diameter and ISICOMP.  However, ISICOMP was significantly correlated with % change in diameter 
normalized to SRAUC (r=0.49, P<0.01) (Fig. 4.4). In addition, the normalized % change in 
diameter was significantly different between IS and IR (P<0.05) (Table 4.3). 
Microvascular Reactivity 
[HbO2] parameters before and during PORH are shown in Table 4.4.  There were no 
significant differences between IS and IR for any of the values.  Additionally there were no 
correlations between any of the blood lipid, CRP or metabolic variables and [HbO2] parameters 
for the subjects as a whole or any subgroup of the subjects.   
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The post-occlusion increase in BABF was a second measure of microvascular reactivity 
and parameters describing this response are also shown in Table 4.4.  In contrast to [HbO2] 
measures of microvascular reactivity, BABF exhibited a multitude of significant differences 
between IS and IR.  Fig. 4.2 portrays the BABF responses for an IS and an IR subject.  BABF at 
rest (R) was significantly greater in IR relative to IS (P<0.05) (Table 4.4) and significantly 
inversely correlated with ISICOMP (r =-0.48, P<0.01) (Fig. 4.5).  K and K’ were significantly 
greater in IR relative to IS (both P<0.03) (Table 4.4) and the former significantly negatively 
correlated with ISICOMP (r =-0.43, P<0.03) (Fig. 4.4) while the latter showed a trend but failed to 
reach significance in correlating with ISICOMP (P<0.07) (data not shown).  In addition, there were 
significant increases in the total hyperemic response from rest (AUC) and blood flow 95 seconds 
after cuff release (95 s) for IR relative to IS (P<0.01 and P<0.05 respectively) (Table 4.4) but 
these parameters did not correlate with ISICOMP.  R was highly significantly correlated with K’ 
(r=0.72, P<0.0001). 
Forearm conductance 
Table 4.5 lists variables influencing conductance and differences in conductance between 
IS and IR subjects.  There was no significant difference between IS and IR for mean arterial 
pressure (MAP), forearm skeletal muscle MR nor were these variables significantly correlated 
with ISICOMP.  However, all measures of conductance were significantly higher for IR relative to 
IS (all P<0.03) and conductance at rest (CR) (r=-0.47, P<0.01) (Fig. 4.5), at peak hyperemia 
(CPH) (r = -0.36, P<0.04) (Fig. 4.5) and at 95 s (C95) (r=-0.44, P<0.01) (data not shown) were all 
significantly negatively correlated with ISICOMP.  Forearm skeletal muscle MR was not correlated 
with CR or CPH but was significantly correlated with C95 (p=0.37, P<0.05). 
Macrovascular reactivity and microvascular reactivity 
Normalized % change in diameter (macrovascular reactivity) was significantly negatively 
correlated with PORH BABF parameters for R (P<0.04), K’ (P<0.02), 95 s (P<0.03), and AUC 
(P<0.03) (microvascular reactivity) (Fig. 4.5).   
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Discussion 
In the present study we assessed macrovascular endothelial function of the brachial artery 
as well as skeletal muscle microvascular reactivity in the forearm using post-occlusive reactive 
hyperemia in healthy, normoglycemic, college-age subjects with a family history of type 2 
diabetes, and related these results to the magnitude of IR. We have extended the findings of 
altered conduit vessel reactivity for those at risk for developing type 2 diabetes to include the 
youngest post-adolescent adult and provide evidence that the degree of vascular impairment is 
relative to the level of IR even in normal glucose tolerance. Specifically, as hypothesized, 
decreasing ISICOMP (increasing IR) was significantly negatively correlated with reduced BA 
reactivity during post-occlusive reactive hyperemia.  Our results strongly emphasize the 
importance of interpreting vascular reactivity data only when dilatory responses have been 
standardized by the stimulus (shear rate).  Using a noninvasive method (NIRS), we also observed 
abnormalities in microvascular structure/vascular reactivity as changes in [HbO2] as well as 
changes in brachial artery blood flow during the 2.5 min. PORH period.  As hypothesized, there 
were significant differences between IR and IS for BABF at rest (R), at peak hyperemia (K and 
K’) and in the magnitude of hyperemia in recovery (AUC and at 95 s) during PORH.  We found 
that decreasing ISICOMP was positively related to R and K.  Further, this enhanced hyperemic 
response relative to decreasing ISICOMP was not correlated with a concurrent higher MAP 
(upstream pressure) but was strongly correlated with an increase in conductance (reduced 
downstream resistance) at rest (CR), at peak hyperemia (CPH) and at 95 s (C95).  However, 
conductance was not related to an increase in forearm skeletal muscle MR at any time point.  
Until now there has been little information regarding microcirculatory responses in first-degree 
relatives of patients with type 2 diabetes (6) and none, to our knowledge in skeletal muscle 
microcirculation. 
Macrovascular Function 
Endothelial dysfunction precedes the advent of cardiovascular disease and is an 
intermediate phenotype to, and plays a pivotal role in, the advent of diabetic vascular pathology. 
There is abundant evidence that frank diabetes is linked to reduced endothelial-mediated dilation 
(9, 16, 85).  Important to the focus of the present research is that 50% of diabetic patients already 
have coronary artery disease at the time of diagnosis and it is not surprising that prediabetic 
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status of impaired fasting glucose (IFG) has been associated with a 25% decrease in endothelial 
vasoreactivity compared with normal glucose tolerant (NGT) subjects (61).  The focus of the few 
previous studies documenting abnormalities in BA reactivity of normoglycemic subjects with a 
family history of type 2 diabetes have been largely group analysis between subjects with family 
history and those with no family history of type 2 diabetes.  Two early studies, using forearm 
blood flow responses to intra-arterial infusion of acetylcholine (Ach), found no difference 
between IR and IS groups (51, 75).  More recently, McSorley et al. found a positive association 
between insulin action and ACh-induced vasodilation (45).  Caution should be used in 
comparing any of these latter studies to the present study since dilation induced by Ach infusion 
is incompletely blocked by L-NMMA, an inhibitor of nitric oxide synthase, indicating that it is 
only partially NO mediated (19).  However, PORH under the specific conditions employed in the 
present protocol (brachial or radial artery specific, 5 minutes distal cuff occlusion without 
ischemic handgrip exercise, in healthy subjects), has been shown to elicit primarily a NO-
dependent response (27, 58, 74) as it can be almost entirely blocked by L-NMMA (37) and 
PORH after 5 min of arterial occlusion is minimally affected by prostaglandin inhibition (48).   
Similarly, recent reports of significant coronary vasomotor dysfunction relative to IR and 
FH of type 2 diabetes have also used pharmacological vasodilation and measured differences in 
myocardial blood flow (32, 55).  Recently, Tesauro et al., using FMD, found a 23.8% lower in 
endothelium-dependent BA vasodilation and decreased IS in normoglycemic offspring of type 2 
diabetes patients compared to controls (70).  Others have also reported similar reduction of BA 
vasodilation during PORH for subjects with FH (10, 24) (23.4% and 39% lower respectively) 
with (23%, (10)) or without (39%, (24))  a concurrent reduction in insulin sensitivity.  
Balletshofer et al. was the first to report a weak but significant correlation (r = 0.38), between 
decreased FMD endothelial function and the magnitude of IR (as determined by euglycemic 
hyperinsulinemic clamp) and a large, (34.6%) reduction in FMD of IR relative to IS subgroups 
(6).  Therefore, the 21% reduction in FMD in IR vs. IS subjects we observed is similar to 
previous findings (10, 70), but substantial differences in methodologies and exclusion criteria 
(e.g., smoking (6) and obesity (10)) make direct comparisons difficult.  Additionally, in all of the 
previous studies subjects were either middle and old aged (10), in their late 30s or older (24, 45, 
60) or “young” subjects who were in their late 20s to mid 30s (6, 70).  To our knowledge, the 
present study is the first to report concurrent vascular and metabolic abnormalities in the 
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youngest of normal glucose tolerant adults (age 18-26), and significant correlation between 
endothelium-dependent FMD and the magnitude of IR. 
Microvascular Function 
Utilizing BABF during PORH we observed that the vasoreactivity of smaller arterioles 
may be impaired very early in individuals at risk for type 2 diabetes.  The literature taken 
together is unequivocal that impaired microvascular reactivity is clearly present in prediabetes, 
but the attendant scenario is far from clear (81).  Forearm blood flow response to ACh have been 
found to be significantly impaired (76) and cutaneous hyperemia to local heating is decreased in 
subjects with IFG relative to normoglycemic subjects (34). Some data have suggested that 
impairment occurs even earlier and may be linked to the etiology of the disease (65).  Skin ACh-
induced vasodilation is also impaired in normal glucose tolerant subjects at risk for type 2 
diabetes (11) but the message is controversial as the antithesis was observed for microvascular 
hyperemia to local heating in a similar cohort (40).   
The latter discussion emphasizes the difficulty of comparing this study to previous 
literature. In a cross section of studies there is heterogeneity of the included IR states, other 
concomitant metabolic syndrome characteristics, and lack of research in relevant tissues.  Data 
acquired on vessels and tissues a (skin, finger nail fold or conjunctiva) assessed by laser Doppler 
fluxmetry (skin pulp blood flow), transcutaneous oxygen tension (TcpO2), iontophoresis (for the 
subdermal delivery of vasoactive drugs), and/or capillaroscopy (light microscopy) (1), may not 
necessarily be relevant to other areas, such as skeletal muscle, as determined in the current study.  
Further, control of the microcirculation may be different for skeletal muscle than for cutaneous 
beds (84).  Microvascular flow is more tightly regulated locally and involves neuronal, humoral 
and metabolic control (54).  There is growing appreciation that there are differences in vascular 
control dependent on the level of the vessel in the vascular tree (62).  As introduced previously, 
the importance of FMD macrovascular vasodilation is the indication of nitric oxide (NO) 
bioavailability as a marker of cardiovascular protection from atherosclerotic processes.  In 
contrast, the role of flow-induced vasodilation in the microcirculation is controversial (62).  NO 
seems to have limited influence in small arterioles relative to larger vessels (54), which may 
explain the lack of difference in the contribution of  NO to cutaneous microvascular dilation in 
patients with type 2 diabetes compared to controls (66).  
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The term “diabetic microangiopathy” implies a common progression but studies indicate 
that different organ beds (skeletal muscle vs. cutaneous) in different subgroups (young vs. old), 
with variability in cofactors (e.g. normotensive vs. hypertensive), can progress through various 
stages of altered vascular control at different rates as accentuated or retarded by different levels 
of glycemic control (71).  Thus, it is not surprising that, contrary to the findings of attenuated 
microvascular dilation (63, 81), or no impairment of microvascular vasodilatory capacity (40) in 
pre-diabetes, a major finding of our study was that disturbances in microvascular function in 
normotensive, college-age adults manifest as an increase in peak, total hyperemic and recovery 
responses in IR subjects relative to IS.  Wajcberg et al. recently observed similar increased total 
postischemic BABF response in IGT patients compared to lean NGT Hispanic adults but no 
differences in peak hyperemic response (78).  Interestingly they found the opposite results (i.e., 
enhanced peak hyperemic but similar recovery characteristics) in Hispanic type 2 diabetic and 
obese children relative to lean NGT children (78). 
In light of these results, though much emphasis has been placed on vascular dysfunction 
as defined as reduced dilation, the physiology of small arterioles and capillaries is also strongly 
related to vasoconstriction such that vascular dysfunction of this characteristic results in both 
capillary hyperperfusion and hypertension (82).  The increased resting blood flow observed in 
the present study is a frequent observation in diabetes, particularly at early stages.  In our 
college-age cohort not only were there significant differences between IS and IR, but resting 
blood flow was significantly higher and was associated with the magnitude of IR.  It has been 
proposed that excessive vasodilation, consequent to enhanced basal blood flow, can cause 
reduced reactive constriction. Similarly, high circulating insulin levels, characteristic of these IR 
but normoglycemic subjects, act to attenuate constriction and thus, enhance skeletal muscle 
blood flow (82).   
In the progression toward microangiopathy, our young adult IR subjects with 
compensatory hyperinsulinemia (as seen during the OGTT) may well be in the initial functional 
stage.  It is a potential scenario that metabolic abnormalities coupled with oxidative stress and 
high sympathetic tone have produced loss of arteriole myogenic responses and lack of normal 
vasoconstriction in terminal arterioles (81) as evidenced in our results. Our results also show that 
even though systolic BP was significantly higher in concert with magnitude of IR in our 
normotensive cohort, when BABF was normalized for differences in mean arterial pressure, the 
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resulting conductance responses were highly correlated with IR.  Thus, a decrease in downstream 
resistance (presumably associated with decrease in microvascular constrictor tone) was a main 
reason for the differences observed in hyperemic response.  Interestingly, differences in 
conductance were not related to muscle MR.  Increased muscle capillarization has also been 
found in pre-diabetic patients (18), but it is beyond the scope of this study to determine whether 
there were similar microvascular structural alterations in our subjects.  The strong positive 
correlation of BABF at rest (R) with the increase in BABF above rest at peak hyperemia (K’) 
indicates that greater microvascular conductance at rest is associated with accentuated 
conductance during PORH in our subjects.  In turn, both are related to the degree of IR. 
Macro vs. Microvasoreactivity 
Several studies have shown no correlation between endothelium-dependent PORH in the 
macrovasculature and the degree of vasoreactivity in the microvasculature.  All of these studies 
used cutaneous laser Doppler imaging either during reactive hyperemia- (64) or acetylcholine-
induced (25, 26) microvascular vasodilation. In contrast, in the present study, we used 
standardized BA responses and BABF as a measure of microvascular reactivity, which has 
revealed a number of significant negative correlations at rest and during PORH between the 
reactivity of a conduit artery and the reactivity of the downstream microvasculature of that 
artery.  We observed that the larger the percent change in  of the BA, the lower was the BABF at 
rest, at peak hyperemia and during recovery (i.e. the smaller the endothelium-derived response of 
the conduit artery the larger the microcirculatory vasodilation). 
Implications 
Our results indicate an attenuated macrovascular endothelium-derived vasoreactivity and 
an abnormal response of smaller arterioles and capillaries in the youngest of adults with a family 
history of type 2 diabetes relative to the magnitude of their insulin resistance.  This suggests, at 
the level of the conduit artery, that these “healthy” college-age students are already at risk for 
atherogenic progression, and that there may already may be structural and functional 
microvascular modifications that may exacerbate their progression toward type 2 diabetes and to 
the microangiopathy all too commonly associated with this disease.  This is important given that 
the current clinical approach for identifying “disease” postdates the progression through 
IR/hyperinsulinemia.  Given the plethora of evidence that the progression to type 2 diabetes 
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could be reduced with lifestyle intervention (29) including diet and exercise (39), and by 
pharmacological intervention (3), early identification of evidence of dysfunction would provide 
time for reversal of the etiology.  
 Additionally, determining microvascular function in the progression may provide better 
insight into the etiology of the disease, both from a vascular and metabolic perspective. It has 
been shown that the enhanced capillary permeability and plasma extravasation associated with 
hyperperfusion and capillary hypertension (53) can result in remodeling of the capillary 
basement membrane (22) and ultimately lead to microvascular failure (71).  In light of the 
growing evidence of certain beneficial effects of agents in the drug arsenal, such as metformin, at 
the level of the smallest vessels (83), improved microvessel functionality may make it imperative 
to be more aggressive in identifying patients earlier in the disease process. 
Study Strengths and Limitations 
In the present study we found endothelial dysfunction in insulin-resistant young adults 
with and without a family history of type 2 diabetes.  The differences we observed in FMD could 
not be attributed to other confounding variables, because we excluded, or did not show any 
difference between IR vs. IS for other cardiovascular risk factors such as hypercholesterolemia, 
hyperlipidemia and hypertension.  Additional attention was given in the protocol to avoid 
vasoactive factors that impact vasomotor tone including temperature of the room, vasoactive 
medications, smoking, exercise, prandial state, patient anxiety and phase of the menstrual cycle 
(14, 38).  While it is controversial what effect antioxidants have on vasoreactivity, we also 
controlled for diet and antioxidant use.  Women were studied in the follicular phase of their 
menstrual cycle, as verified by progesterone (P4) levels, to mitigate the influence of estrogen.  
Repeat measures (3) of FMD helped ensure a true assessment for each subject.  The protocol was 
initiated at the same time in the morning in order to facilitate all three trials within the morning 
as FMD has been shown to be stable during a 2-hr morning period.  Additionally, repetitive 
reactive hyperemia does not cause significant differences across in trials in healthy college 
students (28) 
 Gender was evenly represented in all subjects and within subgroups of FH and no FH.  
But an unequal gender distribution occurred in IS vs. IR subgroups (73% vs. 33% female / male 
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respectively) and may be the reason for the differences between these two groups in height, 
weight, waist circumference, fat free mass and resting brachial artery .   
 Elevated sympathetic activation is common in certain pathologies and has been shown to 
blunt the FMD response (31). Hypertension has also been documented coincident with elevated 
plasma ET-1 (41). The clinical importance of BA FMD testing is the link between FMD and NO 
bioavailability.  Although we have carefully utilized a protocol that produces a stimulus that is 
largely NO mediated, FMD is also a function of other vasoregulatory mechanisms such as 
sympathetic activation and endogenous vasocontrictors.  To minimize these influences, our 
subjects were all young and screened to include only healthy, non-hypertensive individuals and 
the protocol was planned to minimize environmental factors that may increase sympathetic 
outflow.  Nevertheless, although MAP was not different between IS and IR, systolic BP was 
significantly different between the groups (114 + 9 vs. 124 + 7 mmHg), which may contribute to 
the decrement in the FMD response in the IR group.  A recent study has reported an increased 
peripheral sympathetic outflow linked to a decreased endothelial-dependent FMD of healthy 
offspring of type 2 diabetic patients (33).  An alternate explanation is that the increased systolic 
BP reported in the present study is just a concurrent cardiac risk factor that clusters with the IR 
syndrome (4).  This seems highly plausible since systolic BP was not related to FMD (r=0.08). 
 A strength of the present study, in contrast to virtually all research involving FMD done 
to date, is that the data for macrovascular reactivity was standardized for the stimulus.  The 
outcome of this is that intra-subject comparisons are equally weighted when calculating the 
average and, most importantly, that inter-subject differences and group comparisons are a more 
meaningful reflection of physiologic differences and not confounded by magnitude of the 
stimulus.  We have included Fig. 4.1 as an example of potential error that can be introduced 
when variability of the SR stimulus is not accounted for.  When uncorrected, the % change in 
diameter for these two subjects was identical and the customary inference would be that both 
have similar endothelium-dependent vasodilation, vascular health and vasoprotective state. In 
reality, when responses were corrected for the stimulus, there was actually > 2-fold difference in 
the response between the 2 subjects (Fig. 4.4). We have also observed that not taking stimulus 
variability into account can obfuscate results and subsequent conclusions from those results.  A 
main finding of this study was that the magnitude of IR in very young adults is significantly 
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negatively correlated with BA vasoreactivity, a finding that would have been missed without 
correcting changes in BA  (Fig. 4.4). 
The potential affect of resting vascular dimension on the FMD of conduit arteries is not a 
new concept and has resulted in some studies either correcting FMD for baseline  (7, 30, 36) or 
reporting no significant difference in resting BA  (50). In some studies, flow was determined to 
be the same between subgroups as justification for appropriate group comparisons (as reviewed 
by Pyke, K.E. and Tschakovsky, M.E. (58) However, blood flow is actually not the stimulus for 
flow mediated dilation and should not be used to quantify the stimulus.  The awareness of the 
need to correct for shear stress is not new (46, 56-58), but potential erroneous conclusions, such 
as gender differences in vascular reactivity, are common (7, 11, 70). 
As shown in the present study, females, tested in the low estrogen phase of their 
menstrual cycle, do not have intrinsically greater BA reactivity compared to males.  Further, 
smaller arteries are not inherently more reactive than larger arteries (Fig. 4.1).   However, this 
could be another potential confounding influence in studies that have taken BA measurements 
over a wide range of distances from the antecubital fossa (2-15 cm), i.e. have a greater range of 
BA diameters (6, 50, 69, 79), and have not corrected for the differences in stimulus when 
determining the response. 
In the present study we do not have a measure of endothelial- independent vasodilation, 
so we cannot rule out the affects of alterations in smooth muscle function in our results.  While 
there is still some controversy regarding a difference in either nitroglycerine or sodium 
nitroprusside induced vasodilation between IS and IR (69), the majority of studies indicate no 
difference in vascular smooth muscle function between IS and IR subjects (6, 24, 33, 45, 60). 
In the present study we have used 2 different methods to access post-ischemic reactivity.  
Some studies have utilized PORH brachial artery flow parameters as indications of impaired 
downstream microvascular function/structure (46, 77).  With this methodology we found 
significant differences relative to IR.  However, the NIRS [HbO2] parameters did not indicate the 
same enhanced perfusion that BABF parameters did.  Limitations of this technology and the use 
of the [HbO2] signal has been reported previously (72).  
[HbO2] parameters for the initial hyperemic response from rest and from end cuff scaled 
to their respective baselines have been shown to correlate with corresponding BABF parameters 
(Townsend, D.K. Chapter 2). 
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Conclusions 
In this study we found altered conduit vessel reactivity for those at risk for developing 
type 2 diabetes in the youngest post-adolescent adults, and provided evidence that the degree of 
vascular impairment is related to the level of IR even in normal glucose tolerance. Our results 
also strongly emphasize the importance of interpreting data only when BA responses have been 
standardized by the stimulus.  Additionally, we observed significantly increased BABF at rest, 
and an enhanced peak hyperemia, and magnitude of hyperemia in recovery during PORH related 
to IR.  We found that this enhanced hyperemic response relative to the magnitude of IR was not 
correlated with a concurrent increase in mean arterial pressure (upstream pressure) but strongly 
correlated with an increase in conductance (reduced downstream resistance), which was not 
related to an increase in forearm skeletal muscle MR.  Parameters of BABF at rest, peak 
hyperemic response, and magnitude of hyperemia in recovery are also strongly correlated with 
the BA endothelium-derived vasoreactivity. 
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Tables 
Table 4.1 Anthropometric and clinical characteristics for insulin sensitive and insulin 
resistant subjects. 
 
 All subjects IS IR 
 n=26 n=11 n=15 
Gender (female / male) 13/13 8 / 3 5 / 10 
FH type 2 diabetes / no FH 20 / 6 8 / 3 12 / 3 
Age (yr) 21.6 + 2.0 20.9 + 1.8 22.1 + 2.0 
Height (cm) 175 + 9 170 + 7 179.1 + 9† 
Weight (kg) 75.5 + 18.2 62.0 + 8.6 85.3 + 17.1* 
Resting heart rate (bpm) 65.9 + 8.4 68.5 + 7.8 63.3 + 8.5 
Systolic BP (mmHg) 120 + 9 114 + 9 124 + 7* 
Diastolic BP (mmHg) 72.6 + 9.0 70.2 + 6.9 74.4 + 10.2 
Mean BP (mm Hg) 88.3 + 8.1 84.9 + 2.3 90.9 + 2.0 
Waist circumference (cm) 81.9 + 12.6 74.0 + 7.0 88.0 + 12.8* 
Waist-hip ratio 0.79 + 0.08 0.77 + 0.08 0.81 + 0.08 
BMI (kg/m2) 24.4 + 4.4 21.5 + 2.2 26.5 + 4.5* 
Total fat mass (%) 27.8 + 9.6 24.4 + 7.3 30.4 + 10.5 
Abdominal fat (%) 35.1 + 11.0 30.2 + 9.1 38.7 + 11.2‡ 
Fat free mass (kg) 51.6 + 11.7 45.0 + 8.7 56.5 + 11.4† 
 
Significant difference between insulin sensitive (IS) and insulin resistant (IR) subjects †P<0.01, 
*P<0.005, ‡P<0.05. 
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Table 4.2 Biochemical measurements for insulin sensitive and insulin resistant subjects. 
 
 All subjects IS IR 
Blood lipids and CRP n=26 n=11 n=15 
Cholesterol (mg/dl) 161.2 + 28.2 163 + 35 160 + 23 
Triglycerides (mg/dl) 87.1 + 46.9 81.2 + 44.9 91.4 + 49.5 
HDL (mg/dl) 53.2 +15.3 57.2 + 16.7 50.2 + 14.0 
LDLcalc (mg/dl) 90.6 + 22.0 89.4 + 29.0 91.5 + 16.2 
TC/HDL 3.21 + 0.91 3.02 + 1.05 3.36 + 0.81 
LDL/HDL 1.85 + 0.77 1.72 + 0.96 1.95 + 0.61 
Triglycerides / HDL 1.81 + 1.19 1.52 + 0.88 2.02 + 1.37 
C-reactive protein 3.53 + 5.12 2.93 + 3.34 3.97 + 6.20 
Metabolic Characteristics n=25 n=10 n=15 
FI (µU/ml)  5.22 + 2.43 3.45 + 0.52* 6.41 + 2.50 
IAUCOGTT (mIU/l) 3054 + 2113 1757 + 476† 3918 + 2347 
IAVOGTT (mIU/l) 30.7 + 19.1 18.1 + 4.10‡ 39.1 + 20.6 
I2HOGTT (mIU/l) 22.4 + 16.0 14.1 + 6.70§ 28.0 + 18.1 
FG (mg/dl) 84.4 + 6.7 79.7 + 3.18‡ 87.5 + 6.6 
GluAUCOGTT (mIU/l) 3888 + 2286 3411 + 2016 4206 + 2465 
GluAVOGTT (mg/dl) 116 + 21 107 + 18.8 123 + 20 
Glu2HOGTT (mg/dl) 94.1 + 18.6 91.3 + 18.1 96.0 + 19.3 
ISIHOMA 1.05 + 0.45 1.37 + 0.38* 0.84 + 0.35 
ISICOMP 9.88 + 3.98 14.1 + 1.86* 7.1 + 2.0 
 
Significant difference between insulin sensitive (IS) and insulin resistant (IR) subjects *P<0.001, 
†P<0.01, ‡P<0.005, §P<0.05. 
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Table 4.3 Macrovascular stimulus and response in the brachial artery for insulin sensitive 
and insulin resistant subjects. 
 
 All subjects IS IR 
Shear rate (SR) (s-1) n=26 n=11 n=15 
Resting   21.4 + 10.2 17.3 + 6.8 24.6 + 11.5 
Max change  159 + 46 162 + 34 157 + 54 
% change diameter 9.58 + 4.37 10.71 + 4.09 8.68 + 4.53 
AV change-55 s 43.9 + 13.5 44.8 + 9.4 43.2 + 16.4 
Brachial artery diameter (mm)    
Resting  3.92 + 0.66 3.56 + 0.44 4.18 + 0.68* 
% change diameter 7.05 + 3.03 8.03 + 4.24 6.33 + 1.49 
% change diameter / SRAUC 2.75 + 0.84 3.12 + .93 2.48 + 0.68† 
 
Macrovascular stimulus (shear rate (SR) (s-1)) and response (diameter) (mm) in the brachial 
artery.  Significant difference between insulin sensitive (IS)  and insulin resistant (IR) subjects 
*P<0.02, †P<0.05. 
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Table 4.4 Measures of microvascular reactivity prior to and during post occlusive reactive 
hyperemia for insulin sensitive and insulin resistant subjects. 
 
 All subjects IS IR 
[HbO2] n=23 n=11 n=12 
y1  54.3 + 4.5 53.5 + 4.8 55.1 + 4.3 
K 68.9 + 6.6 68.7 + 6.0 69.1 + 7.4 
K %y1 153 + 18 155 + 19 150 + 18 
R 94.1 + 7.3 93.6 + 7.2   94.5 + 7.7 
K’ 24.6 + 2.5 24.5 + 2.4 24.7 + 2.7 
K’ %R 30.7 + 3.6 31.0 + 4.1 30.4 + 3.2 
tm  11.9 + 4.0 12.1 + 5.5 11.7 + 2.1 
d 22.0 + 8.2 24.7 + 10.4 19.5 + 4.7 
tm + 0.5d  22.9 + 7.6 24.5 + 10.2 21.4 + 4.0 
95s 16.3 + 2.6 16.3 + 3.0 16.3 + 2.3 
95s %y1 33.9 + 5.7 34.9 + 6.9 33.1 + 4.4 
95s %K 38.6 + 10.0 35.9 + 9.7 41.1 + 10.1 
95s %R 19.1 + 3.9 19.6 + 4.5 18.7 + 3.5 
95s %K’ 54.4 + 16.3 56.5 + 17.3 52.4 + 16.1 
Forearm ATT (mm) 4.62 + 1.45 4.08 + 1.34 5.03 + 1.45 
BABF n=26 n=11 n=15 
y1 3.28 + 2.58 2.47 + 1.35 3.82 + 4.00 
K  79.7 + 32.1* 61.5 + 16.2 91.8 + 34.8§ 
K %y1 31.5 + 16.7†† 32.2 + 12.5 31.0 + 19.5 
R 10.3 + 7.3 6.63 + 3.43 13.0 + 8.0† 
K’ 67.5 + 24.2*** 55.8 + 15.4 75.5 + 25.9§ 
K’ %R 8.82 + 5.52 10.8 + 6.1 7.28 + 4.47 
AUC 2548 + 975 ** 2039 + 674 2912 + 986* 
95s 6.71 + 5.38† 4.53 + 3.23 8.32 + 5.99‡ 
95s %y1 2.72 + 2.08 2.55 + 1.64 2.83 + 2.39 
95s %K 0.09 + 0.05 0.08 + 0.04 0.09 + 0.06 
95s %R 0.81 + 0.66 0.79 + 0.62 0.81 + 0.69 
95s %K’ 0.10 + 0.08 0.08 + 0.06 0.12 + 0.09 
 
Measures of microvascular reactivity defined by NIRS oxy-hemoglobin ([HbO2]) and brachial 
artery blood flow (BABF) parameters prior to and during post occlusive reactive hyperemia.  
Values at y1=end cuff, K=amplitude from end cuff, R=rest, K’= amplitude from rest, AUC (area 
under the curve brachial artery blood flow from rest) and 95s= amplitude from rest at 95 s. 
Significant difference between insulin sensitive (IS) and insulin resistant (IR) subjects *P<0.01, 
†P<0.02, §P<0.03, ‡P<0.05 (IR column).  Significant positive correlation with systolic blood 
pressure (all subjects column) ***P<0.01, **P<0.02, *P<0.03.  Significant positive correlation 
with forearm skeletal muscle metabolic rate (all subjects column) ††P<0.02, †P<0.05. 
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Table 4.5 Variables influencing and values for conductance for insulin sensitive and insulin 
resistant subjects.  
 
 All IS IR 
Muscle mass (g) 1087 902 1231 
Metabolic rate 4.66 4.43 4.88 
Mean arterial pressure 88.3 84.8 90.9 
Conductance-rest (CR) 0.12 0.07 0.15 
Conductance-peak 0.88 0.73 0.99 
Conductance-95 s (C95) 0.19 0.13 0.24 
 
 
Significant difference between insulin sensitive (IS) and insulin resistant (IR)  subjects *P<0.01, 
†P<0.02, §P<0.03, ‡P<0.05 (IR column).  Positively significantly correlated with metabolic rate 
(all subjects column) ‡P<0.05. 
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Figures 
 
Figure 4.1 Shear rate and brachial artery diameter after post occlusive reactive hyperemia 
for two subjects. 
Time (sec)
-20 0 20 40 60 80 100 120 140
B
ra
ch
ia
l A
rt
er
y 
D
ia
m
et
er
 (m
m
)
2.2
2.4
2.6
2.8
3.0
3.2
3.4
3.6
C
ha
ng
es
 in
 S
R
 (s
-1
) f
ro
m
 re
st
0
5
10
15
20
25
30
Cuff Release
% change in diameter / SRAUC
(a) = 1.90
(b) = 4.02
SRAUC
(a)
SRAUC
(b)
change diameter (a)
change diameter (b)
 
 
Shear rate (SR) (s-1) and brachial artery (BA) diameter (mm) after post occlusive reactive 
hyperemia for two subjects, (a) (black) and (b) (gray).  % change in diameter from the baseline is 
the same for (a) vs. (b) (12.15% and 12.09% respectively).  When the % change in diameter is 
standardized by the SR stimulus (SRAUC), then it is apparent that there actually is > 2 fold 
difference in the response between the two subjects (1.90 vs. 4.02). 
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Figure 4.2 Resting and post occlusive reactive hyperemia responses for brachial artery 
blood flow and % change in brachial artery diameter for an insulin resistant and an insulin 
sensitive subject. 
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Brachial artery (BA) blood flow (BF) (cm3/s) and % change in BA diameter standardized by 
shear rate (SRAUC) (arbitrary units).  Cuff release occurred at t=0.  The insulin resistant (IR) 
subject (ISICOMP = 2.95) is characterized by higher resting BABF (gray vs. black bar), larger 
initial hyperemic response, larger total hyperemic response (gray vs. white fill) and higher blood 
flow above rest at 95s (dotted line) relative to the insulin sensitive (IS) subject (ISICOMP = 13.43).  
Concomitant with these characteristics is a smaller % change BA diameter / SRAUC for the IR 
relative to the IS subject (gray vs. black line). 
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Figure 4.3 Affects of gender and resting brachial artery diameter on % change in brachial 
artery diameter during post occlusive reactive hyperemia. 
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Affects of gender (top panel) and resting brachial artery diameter (resting diam) (bottom panels) 
on % change in brachial artery diameter (% change diameter).  Men have a significantly larger 
resting diameter (*P<0.0001) but % change diameter standardized by the stimulus (area under 
the curve shear rate (AUC SR) is not significantly different between the genders (top panel).  % 
change diameter is significantly correlated with resting diameter (P<0.0003) but not when the 
response is standardized by the stimulus (bottom panels). 
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Figure 4.4 Macrovascular reactivity relative to insulin sensitivity in normoglyncemic 
college-age subjects 
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Brachial artery reactivity (% change in diameter) not standardized by the shear rate stimulus (top 
panel) and standardized by the shear rate stimulus (% change in diameter / SRAUC) (bottom 
panel) over a range of whole-body insulin sensitivities (ISICOMP).  There is significant correlation 
between conduit artery reactivity and insulin sensitivity in these normoglycemic subjects but this 
relationship is only discernable when the response is standardized by the stimulus (bottom panel) 
(P<0.01). 
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Figure 4.5 Parameters of brachial artery blood flow at rest and peak hyperemia and 
conductance at rest and peak hyperemia relative to insulin sensitivity. 
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Parameters of brachial artery blood flow (BABF) at rest (R) and peak hyperemia (K) and 
conductance at rest (CR) and peak hyperemia (CPH) (right figures) relative to insulin sensitivity 
(ISICOMP).  Blood flow parameters R and K are significantly negatively correlated with ISICOMP 
(P<0.01 and P<0.03 respectively) but are significantly correlated with mean arterial pressure.  
Thus, differences in conductance at rest and peak hyperemia, which are also significantly 
negatively correlated with ISICOMP (P<0.01 and P<0.04 respectively), must be the reason for the 
differences in BABF relative to insulin sensitivity at these times. 
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CHAPTER 5 - Conclusions 
Integrating the studies described in this dissertation, we conclude that substantial levels 
of IR and hyperinsulinemia are detectable preceding the deterioration of glucose tolerance in the 
youngest of adults with a family history of type 2 diabetes.  In addition, we observed attenuated 
macrovascular endothelium-derived vasoreactivity and an abnormal response of smaller 
arterioles and capillaries relative to the magnitude of insulin resistance.  This suggests that, at the 
level of the conduit artery, some of these apparently “healthy” college-age students are already at 
risk for atherogenic progression, and that there may already may be structural and functional 
microvascular modifications that will exacerbate their progression toward type 2 diabetes and to 
the microangiopathy all too commonly associated with this disease.   
In the first study (Chapter 2) we quantified a 7-fold range in insulin sensitivity with 58% 
of our subjects, including 37% of our lean subjects, exhibiting levels associated with metabolic 
disorder and frank disease reported in other studies. This was determined from measures of 
fasting insulin and insulin during an OGTT, which proved to be a highly sensitive means of 
quantifying IR in these young adults, while parallel measures of serum glucose were not.  To our 
knowledge, this is the first study to verify the presence of IR in college–age adults with an easily 
applicable indirect measure.   
In the Study 2 (Chapter 3) we found a ~ 2-fold range in forearm skeletal muscle 
metabolic rate in resting conditions, comparable with previous findings based on direct Fick 
method of muscle oxygen uptake.  Additionally, parameters of the post-occlusive reactive 
hyperemia test utilizing near infrared spectroscopy were determined to access microcirculatory 
reactivity and verified by amplitude parameters of brachial artery blood flow (as an independent 
assessment of microcirculatory vasodilatory response).  From the results of this study, it can be 
concluded that NIRS is a useful noninvasive tool for investigating tissue metabolism and 
microvascular reactivity. Strong evidence was provided for the imperative to correct NIRS 
signals for the effects of subcutaneous fat.   
Finally, in Chapter 4 we assessed macrovascular endothelial function of the brachial 
artery as well as skeletal muscle microvascular reactivity in the forearm using post-occlusive 
reactive hyperemia and related these results to the magnitude of IR.  To our knowledge, these 
studies are the first to report concurrent vascular and metabolic abnormalities in the youngest of 
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normal glucose tolerant adults (age 18-26).  A strength of our study, in contrast to virtually all 
research involving flow mediated dilation conducted to date, is verification that the data for 
macrovascular reactivity must be standardized for the stimulus or results will be obfuscated.  
Moreover, a major finding of our study was that disturbances in microvascular function manifest 
as an increase in peak, total hyperemic and recovery responses in IR subjects relative to insulin 
sensitive subjects. Additionally, this enhanced hyperemic response was not correlated with a 
concurrent increase in MAP (upstream pressure), but was strongly correlated with an increase in 
conductance (reduced downstream resistance), which was not related to an increase in forearm 
skeletal muscle MR. 
In conclusion, this body of work furthers our insight into the need for identification of 
“disease” earlier in the natural history of type 2 diabetes.  This seems warranted given the 
plethora of evidence that the progression to type 2 diabetes could be reduced with lifestyle 
intervention.  Furthermore, in light of the growing evidence of certain beneficial effects of agents 
in the drug arsenal, earlier detection allows for earlier intervention to slow the etiology of 
atherogenic progression and to improve abnormal microvessel functionality, both of which have 
been substantiated relative to early IR in college-age adults in this series of studies. 
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